Overview

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Acute Lymphoblastic Leukemia (ALL) were developed as a result of meetings convened by a multidisciplinary panel of experts, with the goal of providing recommendations on standard treatment approaches based on current evidence. The NCCN Guidelines and the following discussions focus on the immunophenotypic classification and cytogenetic/molecular subtypes of ALL, risk assessment and stratification for risk-adapted therapy, treatment strategies for Philadelphia chro-
mosome (Ph)–positive and Ph-negative ALL for both adolescents and young adult (AYA) and adult patients, and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN Acute Lymphoblastic Leukemia Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL.

ALL is a heterogenous hematologic disease characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs. The age-adjusted incidence rate of ALL in the US is 1.7 per 100,000 individuals per year, with approximately 6050 new cases and 1440 deaths estimated in 2012. The median age at diagnosis for ALL is 13 years; 60% of patients are diagnosed at younger than 20 years, whereas 23% are diagnosed at 45 years or older. Only approximately 11% of patients are diagnosed at 65 years or older. ALL represents 75% to 80% of acute leukemias among children, making it the most common form of childhood leukemia; by contrast, ALL represents only approximately 20% of all leukemias among adults.

The cure rates and survival outcomes for patients with ALL have improved dramatically over the past several decades, primarily among children. Improvements are largely owed to advances in the understanding of the molecular genetics and pathogenesis of the disease, incorporation of risk-adapted therapy, and the advent of new targeted agents. With current treatment regimens, the cure rate among children with ALL is approximately 80%. The text continues on p. 876.
Acute Lymphoblastic Leukemia, Version 1.2012

**DIAGNOSIS**

The diagnosis of ALL generally requires demonstration of ≥ 20% bone marrow lymphoblasts on hematopathology review of bone marrow aspirate and biopsy materials, which includes:

- Morphologic assessment of Wright-Giemsa-stained bone marrow aspirate smears, and H&E stained core biopsy and clot sections
- Comprehensive flow cytometric immunophenotyping

**GENETIC CHARACTERIZATION**

Optimal risk stratification and treatment planning requires testing marrow or peripheral blood lymphoblasts for specific recurrent genetic abnormalities using:

- Karyotyping of G-banded metaphase chromosomes (cytogenetics)
- Interphase fluorescence in situ hybridization (FISH) testing, including probes capable of detecting the major recurrent genetic abnormalities
- Reverse transcriptase-polymerase chain reaction (RT-PCR) testing for fusion genes (e.g., BCR-ABL)

Additional optional tests include:

- Flow cytometric DNA index/ploidy testing (additional assessment for hyperdiploidy and hypodiploidy)
- Reverse transcriptase-polymerase chain reaction (RT-PCR) testing for fusion genes

**CLASSIFICATION**

Together, these studies allow determination of the WHO ALL subtype and cytogenetic risk group.

Strongly recommend that patients be treated in specialized centers.

---

Subtypes: B-cell lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities include hyperdiploidy, hypodiploidy, and commonly occurring translocations: t(9;22)(q34;q11.2)[BCR-ABL1]; t(1;19)(q23;p13.3)[E2A-PBX1]; t(5;14)(q31;q32)[IL3-IGH; relatively rare], B-cell lymphoblastic leukemia/lymphoma, not otherwise specified, T-cell lymphoblastic leukemia/lymphoma.

Criteria for classification of mixed phenotype acute leukemia (MPAL) should be based on the WHO 2008 criteria. Note that in ALL, myeloid-associated antigens such as CD13 and CD33 may be expressed, and the presence of these myeloid markers does not exclude the diagnosis of ALL.

Treatment of Burkitt leukemia/lymphoma – see NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Hodgkin's Lymphomas (to view the most recent version of these guidelines, visit NCCN.org).

Although these guidelines pertain primarily to patients with leukemia, patients with lymphoblastic lymphoma (B- or T-cell) would likely also benefit from ALL-like regimens.

See Typical Immunophenotype by Major ALL Subtypes (page 867).

Cytogenetic risk groups are defined as follows:

- Good risk: hyperdiploidy (51-65 chromosomes and/or DNA index > 1.16; cases with trisomy of chromosomes 4, 10, and 17 appear to have the most favorable outcome); t(12;21)(p13;q22): TEL-AML1;
- Poor risk: hypodiploidy (< 44 chromosomes and/or DNA index < 0.81); t(11;q23): MLL rearranged; t(9;22)(q34;q11.2); BCR-ABL; complex karyotype (> 5 chromosomal abnormalities).
Acute Lymphoblastic Leukemia, Version 1.2012

WORKUP

- History and physical (H&P)
- CBC, platelets, differential, chemistry profile
- Disseminated intravascular coagulation (DIC) panel: d-dimer, fibrinogen, prothrombin time (PT), partial thromboplastin time (PTT)
- Tumor lysis syndrome (TLS) panel: lactate dehydrogenase (LDH), uric acid, K, Ca, Phos (See TLS in the NCCN Guidelines for Non-Hodgkins Lymphomas*)
- CT/MRI of head, if neurologic symptoms§
- Lumbar puncture (LP)§
  - See Evaluation and Treatment of Extramedullary Involvement (page 871)
  - Consider intrathecal (IT) chemotherapy
- CT of chest (for patients with T-cell ALL [T-ALL])
- Testicular exam (testicular involvement is especially common in T-ALL)
- Infection evaluation:
  - Screen for active infections if febrile or for symptomatic opportunistic infections
  - Initiate empirical treatment, as appropriate (See NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections*)
- Echocardiogram or cardiac scan should be considered in all patients, because anthracyclines are important components of ALL therapy, but especially in patients with prior cardiac history and prior anthracycline exposure with clinical symptoms suggestive of cardiac dysfunction.
- Central venous access device of choice
- Human leukocyte antigen (HLA) typing (except for patients with a major contraindication to hematopoietic stem cell transplant [HSCT])
- In patients with poor-risk features who lack a sibling donor, consider early evaluation for an alternative donor search

RISK STRATIFICATION

- Ph+ ALL (adolescents and young adults [AYA]) — See Treatment (page 862)
- Ph+ ALL (Adult) — See Treatment (page 863)
- Ph- ALL (AYA) — See Treatment (page 864)
- Ph- ALL (Adult) — See Treatment (page 865)

*To view the most recent version of these guidelines, visit NCCN.org.

§For patients with major neurologic signs or symptoms at diagnosis, appropriate imaging studies should be performed to detect meningeal disease, chloromas, or central nervous system (CNS) bleeding. See Evaluation and Treatment of Extramedullary Involvement (page 871).

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 10 Number 7 | July 2012
Acute Lymphoblastic Leukemia, Version 1.2012

Clinical trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 10 Number 7 | July 2012
Acute Lymphoblastic Leukemia, Version 1.2012

RISK STRATIFICATION

TREATMENT INDUCTION

CONSOLIDATION THERAPY

Patients < 65 years of age\(^1\) or with no substantial comorbidities

Clinical trial or Chemotherapy\(^1\) + TKI\(^m\)

CR\(^n\) → Consider monitoring for MRD\(^o\)

Less than CR\(^n\) → See Relapse/Refractory Disease (page 866)

Consider post-HSCT TKI\(^m\)

Allogeneic HSCT, if a donor is available or if an allogeneic HSCT donor is not available, continue multiagent chemotherapy\(^1\)\(^r\) + TKI\(^m\)

Maintenance therapy\(^1\) + TKI\(^m\)

See Surveillance (page 866)

Patients ≥ 65 years of age\(^1\)\(^q\) or with substantial comorbidities

Ph+ ALL (adult) (age ≥ 40 y)

Clinical trial or TKI\(^m\) + corticosteroids\(^1\) or TKI\(^m\) + chemotherapy\(^1\)\(^r\)

CR\(^n\) → Continue TKI\(^m\) + corticosteroids\(^1\) or Continue TKI\(^m\) + chemotherapy\(^1\)

Less than CR\(^n\) → See Relapse/Refractory Disease (page 866)

Maintenance therapy\(^1\) + TKI\(^m\)

See Surveillance (page 866)

\(^1\)Chronologic age is a poor surrogate for fitness for therapy. Patients should be evaluated on an individual basis, including for the following factors: end-organ reserve, end-organ dysfunction, and performance status.

\(^2\)All ALL treatment regimens include CNS prophylaxis.

\(^3\)See Principles of Chemotherapy (pages 872 and 873).

\(^4\)See Discussion section for use of different TKIs in frontline therapy.

\(^5\)See Response Criteria (page 874).

\(^6\)See Minimal Residual Disease Assessment (page 874).

\(^7\)For additional considerations in the management of senior adult patients with ALL, see the NCCN Guidelines for Senior Adult Oncology (to view the most recent version of these guidelines, visit NCCN.org).

\(^8\)Consider dose modifications appropriate for patient age and performance status.
Acute Lymphoblastic Leukemia, Version 1.2012

Clinical trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.
Acute Lymphoblastic Leukemia, Version 1.2012

**RISK STRATIFICATION**

Patients < 65 years of age or with no substantial comorbidities

Ph- ALL (adult) (aged ≥ 40 y)

Patients ≥ 65 years of age or with substantial comorbidities

**TREATMENT INDUCTION**

CR\textsuperscript{n} → Consider monitoring for MRD\textsuperscript{p}

Less than CR\textsuperscript{n}

Clinical trial or Multiagent chemotherapy\textsuperscript{s}

CR\textsuperscript{n} → Consider allogeneic HSCT if a donor is available (especially MRD+, WBC count ≥ 30 x 10\textsuperscript{9}/L [B lineage] or ≥ 50 x 10\textsuperscript{9}/L [T lineage], hypodiploidy, or MLL rearrangement)

See Relapse/Refractory Disease (page 866)

**CONSOLIDATION THERAPY**

Continue multiagent chemotherapy (especially MRD-)

Chemotherapy\textsuperscript{l}

See Relapse/Refractory Disease (page 866)

Maintenance therapy\textsuperscript{j}

**Surveillance** (page 866)

\textsuperscript{1}Chronologic age is a poor surrogate for fitness for therapy. Patients should be evaluated on an individual basis, including for the following factors: end-organ reserve, end-organ dysfunction, and performance status.

\textsuperscript{2}All ALL treatment regimens include CNS prophylaxis.

\textsuperscript{3}See Principles of Chemotherapy (pages 872 and 873).

\textsuperscript{4}See Response Criteria (page 874).

\textsuperscript{5}See Minimal Residual Disease Assessment (page 874).

\textsuperscript{6}For additional considerations in the management of senior adult patients with ALL, see the NCCN Guidelines for Senior Adult Oncology (to view the most recent version of these guidelines, visit NCCN.org).

\textsuperscript{7}See Principles of Chemotherapy (pages 872 and 873). All regimens include induction/delayed intensification (especially for pediatric-inspired regimens) and maintenance therapy.

\textsuperscript{8}Benefit with allogeneic HSCT is unclear in this setting.

\textsuperscript{9}Data demonstrating the effect of WBC counts on prognosis are less firmly established for adults than for the pediatric population.
SURVEILLANCE

Year 1 (every 1-2 mo):
- Physical exam, CBC with differential every month
- Liver functions tests (LFTs) every 2 months until normal
- Bone marrow aspirate, cerebrospinal fluid (CSF), and echocardiogram as indicated
  - If bone marrow aspirate is performed: comprehensive cytogenetics, FISH, flow cytometry, and consideration of molecular tests

Year 2:
- Physical exam, including testicular exam, CBC with differential every 3 mo

Year 3+:
- Refer to Survivorship recommendations in the NCCN Guidelines for Adolescent and Young Adult Oncology (to view the most recent version of these guidelines, visit NCCN.org)
- Refer to the ALL Long-Term Follow-Up Guidelines from Children’s Oncology Group (COG): www.survivorshipguidelines.org

RELAPSE/REFRACTORY DISEASE

Ph+ ALL (AYA) → Consider ABL gene mutation testing

Ph+ ALL (adult) → Consider ABL gene mutation testing

Ph- ALL (AYA) → Relapse/refractory

Ph- ALL (adult) → Consider ABL gene mutation testing

TREATMENT

Consider clinical trial or TKI\textsuperscript{m} ± chemotherapy\textsuperscript{y}
or Allogeneic HSCT (if remission achieved) or Donor lymphocyte infusion (if prior allogeneic HSCT)

Consider clinical trial or Allogeneic HSCT (if remission achieved) or TKI\textsuperscript{m} ± corticosteroids or TKI\textsuperscript{m} ± chemotherapy\textsuperscript{y}

Consider clinical trial or Allogeneic HSCT (if remission achieved) or Chemotherapy\textsuperscript{y, z}

Consider clinical trial or Consider allogeneic HSCT (if remission achieved) or Chemotherapy\textsuperscript{y}

\textsuperscript{m}See Discussion section for use of different TKIs in this setting.
\textsuperscript{y}Surveillance recommendations apply after completion of chemotherapy, including maintenance.
\textsuperscript{w}Isolated extramedullary relapse (both CNS and testicular) requires systemic therapy to prevent relapse in marrow.
\textsuperscript{x}See Treatment Options Based on BCR-ABL Kinase Domain Mutation Status (page 875).
\textsuperscript{y}See Principles of Chemotherapy (pages 872 and 873 for regimens not previously used for induction therapy and salvage regimens).
\textsuperscript{z}Nelarabine is available for patients with relapsed T-ALL.
\textsuperscript{z}Clofarabine is available for relapsed pre-B-ALL in patients age ≤ 21 y.
\textsuperscript{z}For late relapse (> 3 y from initial diagnosis), consider treatment with the same induction regimen (see pages 872 and 873).
Acute Lymphoblastic Leukemia, Version 1.2012

**Typical Immunophenotype by Major ALL Subtypes**

The initial immunophenotyping panel should be sufficiently comprehensive to establish a leukemia-associated phenotype (LAP) that may include expression of nonlineage antigens. These LAPs are useful in classification, particularly mixed-lineage leukemias, and as a signature for MRD detection.

**B-ALL, not otherwise specified:** CD10+, CD19+, CD79a+, cCD22+, sCD22+, CD24+, PAX5+, TdT+, variable CD20, variable CD34
- Early precursor B-ALL (pro-B-ALL): CD10-, CD19+, cCD79a, cCD22+, TdT+
- Common B-ALL: CD10+
- Precursor B-ALL (pre-B-ALL): cytoplasmic μ+, slg-, CD10+/-

**B-ALL with recurrent genetic abnormalities:**
- Hyperdiploidy (DNA index > 1.16; 51-65 chromosomes without structural abnormalities): CD10+, CD19+, CD34+, CD45
- Hypodiploidy (< 46 chromosomes): CD10+, CD19+, CD34+
- t(9;22)(q34;q11.2); BCR-ABL1: CD10+, CD19+, TdT+, CD13+, CD33+, CD117-
- t(v;11q23); MLL rearranged: CD10-, CD19+, CD24-, CD15+
- t(12;21)(p13;q22); TEL-AML1: CD10+, CD19+, TdT+, CD13+, CD34+
- t(1;19)(q23;p13.3); E2A-PBX1: CD10+, CD19+, CD20 variable, CD34 -/+; cytoplasmic μ+
- t(5;14)(q31;q32); IL3-IGH: CD10+, CD19+

**T-ALL:** TdT+, variable for all of the following: CD1a, CD2, CD3, CD4, CD5, CD7, CD8, CD34
- Pro-T-ALL:** cCD3+, CD7+, CD1a-, CD2-, CD4-, CD8-, CD34+/-
- Pre-T-ALL:** cCD3+, CD7+, CD1a-, CD2-, CD4-, CD8-, CD34+/-
- Cortical T-ALL:** cCD3+, CD7+, CD1a+, CD2+, CD4+, CD8+, CD34-
- Medullary T-ALL:** cCD3+, sCD3+, CD7+, CD1a-, CD2+, CD4+, or CD8+, CD34-

SUPPORTIVE CARE

Best supportive care

- Infection control (See NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections*)
  - Prophylactic antibiotics
    - Antibacterial prophylaxis: consider fluoroquinolones
    - Antiviral prophylaxis: during periods of neutropenia (and at least 30 days after HSCT for transplant recipients), herpes simplex virus (HSV) prophylaxis (e.g., acyclovir, famciclovir, valacyclovir)
    - Cytomegalovirus (CMV) infection management: consider CMV monitoring and preemptive therapy with intravenous ganciclovir, intravenous foscarnet, or oral valganclovir for all patients; for patients undergoing allogeneic HSCT, CMV monitoring and preemptive therapy strongly recommended until at least 6 months after transplantation
    - Antifungal prophylaxis: consider prophylaxis with fluconazole or amphotericin B agent for all patients treated with chemotherapy; for patients undergoing allogeneic HSCT, antifungal prophylaxis with fluconazole or micafungin strongly recommended until at least day 75 after transplantation
    - Pneumocystis pneumonia (PCP) prophylaxis: trimethoprim-sulfamethoxazole (TMP-SMX)
  - Infection control
    - Heightened awareness for risk of sepsis/death from steroid therapy and neutropenia
    - Febrile neutropenia management
      - Fever is defined as a single temperature ≥ 38.3°C (101°F) or ≥ 38.0°C (100.4°F) over a 1-hour period
      - Intravenous antibiotics/inpatient admission
  - Acute TLS (See Tumor Lysis Syndrome in the NCCN Guidelines for Non-Hodgkin’s Lymphomas*)
  - Asparaginase toxicity management - see pages 869 and 870
  - Steroid management
    - Acute side effects
      - Steroid-induced diabetes mellitus
      - Use of filgrastim (granulocyte colony-stimulating factor [G-CSF])
        - 5 mcg/kg/d subcutaneously (recommended for myelosuppressive blocks of therapy or as directed by treatment protocol)
      - Hyperleukocytosis
        - Although uncommon in patients with ALL, symptomatic hyperleukocytosis may require emergent treatment (See Symptomatic Leukocytosis in the NCCN Guidelines for Acute Myeloid Leukemia*)
    - Antiemetics (See NCCN Guidelines for Antiemesis*)
      - Given as needed before chemotherapy and post chemotherapy
    - Gastroenterology
      - Consider starting a bowel regimen to avoid constipation
      - Docusate sodium daily
      - Laxatives promptly considered and used if symptoms arise
    - Nutritional support
      - Consider enteral or parenteral support for > 10% weight loss
  - Palliative treatment for pain (See NCCN Guidelines for Adult Cancer Pain*)

To view the most recent version of these guidelines, visit NCCN.org.
Acute Lymphoblastic Leukemia, Version 1.2012

SUPPORTIVE CARE

Asparaginase Toxicity Management

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Toxicity Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic allergic reaction/ anaphylaxis</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Permanent discontinuation of PEG-asparaginase</td>
<td>PEG-asparaginase or native <em>Escherichia coli</em> asparaginase; substitute asparaginase <em>Erwinia chrysanthemi</em> as follows: To substitute for a dose of PEG-asparaginase: the recommended dose is 25,000 IU/m² intramuscularly 3 times per week (Monday/Wednesday/Friday) for 6 doses for each planned dose of PEG-asparaginase. To substitute for a dose of native <em>E coli</em> asparaginase: the recommended dose is 25,000 IU/m² intramuscularly for each scheduled dose.</td>
</tr>
<tr>
<td></td>
<td>4</td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>Continue asparaginase for asymptomatic amylase or lipase elevation &gt; 3.0 x ULN (chemical pancreatitis) or only radiologic abnormalities; observe closely for rising amylase or lipase levels.</td>
</tr>
<tr>
<td></td>
<td>Continue PEG-asparaginase for non-symptomatic chemical pancreatitis but observe patient closely for development of symptomatic pancreatitis for early treatment. Hold native asparaginase for amylase or lipase elevation &gt; 3.0 x ULN until enzyme levels stabilize or are declining. Permanently discontinue asparaginase for symptomatic pancreatitis.</td>
</tr>
<tr>
<td></td>
<td>Permanently discontinue all asparaginase for clinical pancreatitis (vomiting, severe abdominal pain) with amylase or lipase elevation &gt; 3 x ULN for &gt; 3 d and/or development of pancreatic pseudocyst.</td>
</tr>
<tr>
<td>Hepatic transferasemia</td>
<td>For alanine or glutamine aminotransferase elevation &gt; 3.0-5.0 x ULN, continue asparaginase.</td>
</tr>
<tr>
<td></td>
<td>For alanine or glutamine aminotransferase elevation &gt; 5.0-20.0 x ULN, delay next dose of asparaginase until grade &lt; 2.</td>
</tr>
<tr>
<td></td>
<td>For alanine or glutamine aminotransferase elevation &gt; 20.0 x ULN, discontinue asparaginase if toxicity reduction to grade &lt; 2 takes &gt; 1 wk.</td>
</tr>
<tr>
<td>Hyper-bilirubinemia</td>
<td>Continue asparaginase if direct bilirubin &lt; 3.0 mg/dL.</td>
</tr>
<tr>
<td></td>
<td>If direct bilirubin 3.1-5.0 mg/dL, hold asparaginase and resume when direct bilirubin is &lt; 2.0 mg/dL. Consider switching to native asparaginase.</td>
</tr>
<tr>
<td></td>
<td>If direct bilirubin &gt; 5.0 mg/dL, discontinue all asparaginase and do not make up for missed doses.</td>
</tr>
</tbody>
</table>

Cont. on page 870.

### Asparaginase Toxicity Management

#### Toxicity Grade

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-CNS</strong></td>
<td>For abnormal laboratory findings without clinical correlates, continue asparaginase.</td>
<td>Withhold asparaginase until acute toxicity and clinical signs resolve and anticoagulant therapy stable or completed; do not withhold asparaginase for abnormal laboratory findings without a clinical correlate.</td>
<td>Withhold asparaginase until acute toxicity and clinical signs resolve and anticoagulant therapy stable or completed.</td>
</tr>
<tr>
<td>thrombosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Non-CNS</strong></td>
<td>For bleeding in conjunction with hypofibrinogenemia, withhold asparaginase until bleeding ≤ grade 1; do not withhold asparaginase for abnormal laboratory findings without a clinical correlate.</td>
<td>Withhold asparaginase until bleeding ≤ grade 1, acute toxicity and clinical signs resolve, and coagulant replacement therapy stable or completed.</td>
<td>Withhold asparaginase until bleeding ≤ grade 1, acute toxicity and clinical signs resolve, and coagulant replacement therapy stable or completed.</td>
</tr>
<tr>
<td>hemorrhage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>For abnormal laboratory findings without a clinical correlate, continue asparaginase.</td>
<td>Discontinue all asparaginase; if CNS symptoms and signs are fully resolved and significant asparaginase remains to be administered, may resume asparaginase therapy at a lower dose and/or longer intervals between doses.</td>
<td>Permanently discontinue all asparaginase.</td>
</tr>
<tr>
<td>thrombosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Discontinue asparaginase; do not withhold asparaginase for abnormal laboratory findings without a clinical correlate.</td>
<td>Discontinue all asparaginase; if CNS symptoms and signs are fully resolved and significant asparaginase remains to be administered, may resume asparaginase therapy at a lower dose and/or longer intervals between doses.</td>
<td>Permanently discontinue all asparaginase.</td>
</tr>
<tr>
<td>hemorrhage</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Acute Lymphoblastic Leukemia, Version 1.2012

EVALUATION AND TREATMENT OF EXTRAMEDULLARY INVOLVEMENT

- Given the risks of neurotoxicity associated with central nervous system (CNS)-directed therapy, baseline and posttreatment comprehensive neuropsychological testing may be useful.
- The aim of CNS prophylaxis and/or treatment is to clear leukemic cells within sites that cannot be readily accessed by systemic chemotherapy due to the blood-brain barrier, with the overall goal of preventing CNS disease or relapse.
- Factors associated with increased risks for CNS leukemia in adults include mature B-cell immunophenotype, T-cell immunophenotype, high presenting WBC counts, and elevated serum LDH levels.\(^1\)\(^2\)
- CNS involvement should be evaluated (by LP) at the appropriate timing:
  - Timing of LP should be consistent with the chosen treatment regimen.
  - Pediatric-inspired regimens typically include LP at the time of diagnostic workup.
  - The panel recommends that LP, if performed, be done concomitantly with initial IT therapy.
- Classification of CNS status:
  - CNS-1: No lymphoblasts in CSF regardless of WBC count
  - CNS-2: WBC < 5/mcL in CSF with presence of lymphoblasts
  - CNS-3: WBC ≥ 5/mcL in CSF with presence of lymphoblasts
- If the patient has leukemic cells in the peripheral blood and the LP is traumatic and WBC ≥ 5/mcL in CSF with blasts, then compare the CSF WBC/RBC ratio with the blood WBC/RBC ratio. If the CSF ratio is at least 2-fold greater than the blood ratio, then the classification is CNS-3; if not, then it is CNS-2.
- All patients with ALL should receive CNS prophylaxis. Although the presence of CNS involvement at the time of diagnosis is uncommon (approximately 3%-7%), a substantial proportion of patients (> 50%) will eventually develop CNS leukemia in the absence of CNS-directed therapy.
- CNS-directed therapy may include cranial irradiation, IT chemotherapy (e.g., methotrexate, cytarabine, corticosteroids), and/or high-dose systemic chemotherapy (e.g., methotrexate, cytarabine, mercaptopurine, L-asparaginase).
- CNS leukemia (CNS-3) at diagnosis typically warrants treatment with cranial irradiation of 18 Gy. The recommended dose of radiation, where given, is highly dependent on the intensity of systemic chemotherapy; thus, it is critical to adhere to a given treatment protocol in its entirety.
- Note that areas of the brain targeted by the radiation field in the management of ALL are different from areas targeted for brain metastases of solid tumors.
- With the incorporation of adequate systemic chemotherapy (e.g., high-dose methotrexate, cytarabine) and IT chemotherapy regimens (e.g., methotrexate alone or with cytarabine and a corticosteroid, which constitutes the triple IT regimen), it may be possible to avoid the use of upfront cranial irradiation except in cases of overt CNS leukemia at diagnosis, and to reserve the use of irradiation for salvage therapy settings.
- Adequate systemic therapy should be given in the management of isolated CNS relapse.
- Patients with clinical evidence of testicular disease at diagnosis that is not fully resolved by the end of the induction therapy should be considered for radiation to the testes, which is typically performed concurrently with the first cycle of maintenance chemotherapy.

Maintenance regimens:

**Induction Regimens** for Ph-Negative ALL

- **Adult patients aged ≥ 40 y:**
  - TKIs + hyper-CVAD: imatinib or dasatinib; and hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate and cytarabine.*1,4*
  - TKIs + multiagent chemotherapy: imatinib; and daunorubicin, vincristine, prednisone, and cyclophosphamide.*5,6*
  - TKIs + corticosteroids: imatinib and prednisone (for this study, patients were aged > 60 y)*7
  - Dasatinib*8,9*

**Pediatric-inspired protocols for AYA patients aged 15-39 y:**

- COG AALL-0031 regimen: vincristine, prednisone (or dexamethasone), and asparaginase, with or without daunomycin; or prednisone (or dexamethasone) and asparaginase with or without daunomycin; imatinib added during consolidation blocks*10

**Maintenance regimens:**

- Weekly methotrexate + daily 6-mercaptopurine (6-MP)** + monthly vincristine/prednisone pulses (for 2-3 y)
- Add TKIs (imatinib or dasatinib) to the above maintenance regimen

**Induction Regimens** for Ph-Positive ALL

- **Adult patients aged ≥ 40 y:**
  - CALGB 8811 Larson regimen: daunorubicin, vincristine, prednisone, asparaginase, and cyclophosphamide; for patients aged ≥ 60 y, reduced doses for cyclophosphamide, daunorubicin, and prednisone*11
  - Linker 4-drug regimen: daunorubicin, vincristine, prednisone, and asparaginase*12
  - Hyper-CVAD +/- rituximab: hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate and cytarabine; with or without rituximab for CD20-positive disease*3,14
  - MRC UKALL XII/ECOG 2993 regimen: daunorubicin, vincristine, prednisone, and asparaginase (induction phase I); and cyclophosphamide, cytarabine, and 6-MP** (induction phase II)*15

**Pediatric-inspired protocols for AYA patients aged 15-39 y:**

- GRAALL-2003 regimen: daunorubicin, vincristine, prednisone, asparaginase, and cyclophosphamide (patients aged < 60 y)*16
- COG AALL-0434 regimen with nelarabine (for T-ALL): daunorubicin, vincristine, prednisone, and asparaginase; nelarabine added to consolidation regimen (ongoing study)*17
- CCG-1961 regimen: daunorubicin, vincristine, prednisone, and asparaginase (patients aged 21 y)*18,19
- PHEMA ALL-96 regimen: daunorubicin, vincristine, prednisone, asparaginase, and cyclophosphamide (patients aged < 30 y)*20
- CALGB 10403 regimen: daunorubicin, vincristine, prednisone, and asparaginase (ongoing study in patients aged < 40 y)
- DFCI ALL regimen based on DFCI Protocol 00-01: doxorubicin, vincristine, prednisone, high-dose methotrexate, and asparaginase (ongoing study in patients aged < 50 y)*21

**Maintenance regimen:**

- Weekly methotrexate + daily 6-MP** + monthly vincristine/prednisone pulses (for 2-3 y)

**Salvage Regimens** for Relapsed/Refractory ALL

**Ph-positive ALL:**

- Dasatinib*22,23
- Nilotinib*24

**Ph-negative ALL:**

- Clofarabine*25
- Cytarabine-containing regimen*26
- Alkylator combination regimen*27
- Nelarabine (for T-ALL)*28
- Augmented hyper-CVAD: hyperfractionated cyclophosphamide, intensified vincristine, doxorubicin, intensified dexamethasone, and asparaginase; alternating with high-dose methotrexate and cytarabine*29

See references on facing page.

---

*All regimens include CNS prophylaxis with systemic therapy (e.g., methotrexate, cytarabine, 6-MP) and/or IT therapy (e.g., IT methotrexate, IT cytarabine; triple IT therapy with methotrexate, cytarabine, corticosteroid).

**For patients receiving 6-MP, consider testing for TPMT gene polymorphisms, particularly in patients who develop severe neutropenia after starting 6-MP.
Acute Lymphoblastic Leukemia, Version 1.2012

PRINCIPLES OF CHEMOTHERAPY (Cont.)

References


Response Criteria for Blood and Bone Marrow:

- Complete response (CR)
  - No circulating blasts or extramedullary disease
  - No lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement
  - Trilinage hematopoiesis (TLH) and < 5% blasts
  - Absolute neutrophil count (ANC) > 1000/mcL
  - Platelets > 100,000/mcL
  - No recurrence for 4 wk
- CR with incomplete blood count recovery (CRi)
- Relapsed disease
  - Failure to achieve CR at the end of induction
  - Progressive disease (PD)
  - Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease
- Relapsed disease

Response Criteria for CNS Disease:

- CNS remission: achievement of CNS-1 status (see page 871) in a patient with CNS-2 or CNS-3 status at diagnosis.
- CNS relapse: new development of CNS-3 status or clinical signs of CNS leukemia, such as facial nerve palsy, brain/eye involvement, or hypothalamic syndrome.

Response Criteria for Mediastinal Disease:

- CR: complete resolution of mediastinal enlargement by CT.
- CR unconfirmed (CRu): residual mediastinal enlargement that has regressed by > 75% in the sum of the product of the greatest perpendicular diameters (SPD).
- Partial response (PR): > 50% decrease in the SPD of the mediastinal enlargement.
- PD: > 25% increase in the SPD of the mediastinal enlargement.
- No response (NR): failure to qualify for PR or PD.
- Relapse: recurrence of mediastinal enlargement after achieving CR or CRu.

Minimal Residual Disease Assessment

- MRD in ALL refers to the presence of leukemic cells below the threshold of detection using conventional morphologic methods. Patients who achieved a CR on morphologic assessment alone can potentially harbor a large number of leukemic cells in the bone marrow.
- Studies in both children and adults with ALL have demonstrated the strong correlation between MRD and risks for relapse, and the prognostic significance of MRD measurements during and after initial induction therapy.
- The most frequently used methods for MRD assessment include multicolor flow cytometry to detect abnormal immunophenotypes and real-time quantitative polymerase chain reaction (RQ-PCR) assays to detect fusion genes (e.g., BCR-ABL1), clonal rearrangements in immunoglobulin (Ig) heavy chain genes, and/or T-cell receptor (TCR) genes.
- Current multicolor flow cytometry or PCR methods can detect leukemic cells at a sensitivity threshold of < 1 × 10^{-1} (< 0.01%) bone marrow mononuclear cells (MNCs). The concordance rate for detecting MRD between these methods is generally high. The combined or tandem use of both methods allows for MRD monitoring in all patients, thereby avoiding potential false-negative results.
  - Timing of MRD assessment:
    - Upon completion of initial induction.
    - Additional time points may be useful depending on the regimen used.
  - Multicolor flow cytometry: sampling of bone marrow MNCs is preferred over peripheral blood samples; this requires at least 1 × 10^6 MNCs for analysis (about 2 mL of bone marrow or 5-10 mL of peripheral blood provides a sufficient number of cells for multiple analysis).
  - RQ-PCR: sampling of bone marrow MNCs is preferred; this requires at least 1 × 10^6 MNCs for initial marker characterization and generation of individual dilution series; 1 × 10^6 MNCs are sufficient for follow-up analysis.
  - The minimal limit of assay sensitivity (to declare MRD negativity) should be < 1 × 10^{-5} (< 0.01%).
  - High-sensitivity PCR assays (for analysis of Ig or TCR gene rearrangements) require the identification of patient-specific markers that involve direct sequencing, and may therefore be labor- and resource-intensive for routine application in the clinical practice setting.
  - Recommendations on the minimal technical requirements for MRD assessment (both for PCR and flow cytometry methods) and definitions for response based on MRD results (e.g., MRD negativity, nonquantifiable MRD positivity, quantifiable MRD positivity) have recently been published as a result of a consensus development meeting held by ALL study groups across Europe. The recommendations were made in an effort to standardize MRD measurements and MRD data reporting within the context of clinical trials.
  - MRD evaluations should be performed in reference laboratories with expertise in MRD assays; note that results from one laboratory to another may not be directly equivalent or comparable.

---

### TREATMENT OPTIONS BASED ON BCR-ABL KINASE DOMAIN MUTATION STATUS

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Treatment Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>T315I</td>
<td>HSCT or clinical trial</td>
</tr>
<tr>
<td>V299L, T315A, F317L/V/I/C</td>
<td>Consider nilotinib rather than dasatinib</td>
</tr>
<tr>
<td>Y253H, E255K/V, F359V/C/I</td>
<td>Consider dasatinib rather than nilotinib</td>
</tr>
<tr>
<td>Any other mutation</td>
<td>Consider high-dose imatinib&lt;sup&gt;2&lt;/sup&gt; or dasatinib or nilotinib</td>
</tr>
</tbody>
</table>

<sup>1</sup>This research was originally published in Blood. Soverini S, Hochhaus A, Nicolini FE, et al. Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011;118:1208-1215. © the American Society of Hematology

<sup>2</sup>Insufficient data on dose escalation are available to indicate if mutations with lower IC50 values are sensitive to high-dose imatinib.
long-term prognosis for adults with ALL, however, remain poor, with cure rates of only 30% to 40%. This difference in long-term outcomes can be explained partly by differences in the frequency of certain cytogenetic subtypes of ALL among age groups. For example, ALL characterized by the presence of the TEL-AML1 fusion gene is more frequently observed among children (22% of cases) compared with adults (2%), and is associated with a favorable prognosis. In addition, hyperdiploidy (> 50 chromosomes) is more common among children (25%) than adults (7%), and is also associated with favorable outcomes. ALL characterized by the BCR-ABL fusion gene—resulting from chromosomal translocation t(9;22) (Ph)—carries a poor prognosis and is much less common among children (3%) than adults with ALL (25%). The cure rates for AYAs with ALL remain suboptimal (5- to 7-year event-free survival rates from 60%–70%) compared with those for children, although these outcomes represent substantial improvements with the recent adoption of pediatric treatment regimens. AYA patients represent a unique population, because they may receive treatment based on either a pediatric or an adult protocol, depending on local referral patterns and institutional practices. Favorable cytogenetic subtypes, such as TEL-AML1 ALL and hyperdiploidy, occur less frequently among AYA patients compared with children, whereas the incidence of ALL with BCR-ABL (Ph-positive ALL) is higher in AYA patients.

Diagnosis

Clinical Presentation and Diagnosis

The clinical presentation of ALL is typically nonspecific, and may include fatigue or lethargy, constitutional symptoms (fevers, night sweats, weight loss), dyspnea, dizziness, infections, and easy bruising or bleeding. Among children, pain in the extremities or joints may be the only presenting symptoms. The presence of lymphadenopathy, splenomegaly, and/or hepatomegaly on physical examination may be found in approximately 20% of patients. Abdominal masses from gastrointestinal involvement, or chin numbness resulting from cranial nerve involvement, are more suggestive of mature B-cell ALL.

The diagnosis of ALL generally requires demonstration of 20% or greater bone marrow lymphoblasts on hematopathology review of bone marrow aspirate and biopsy materials. The 2008 WHO classification lists ALL and lymphoblastic lymphoma as the same entity, distinguished only by the primary location of the disease. When the disease is restricted to a mass lesion primarily involving nodal or extranodal sites with no or minimal involvement in blood or bone marrow (generally defined as < 20% lymphoblasts in the marrow), the case would be consistent with a diagnosis of lymphoblastic lymphoma. Patients with lymphoblastic lymphoma generally benefit from treatment with ALL-like regimens.

Hematopathology evaluations should include morphologic examination of malignant lymphocytes using Wright-Giemsa-stained slides and hematoxylin and eosin (H&E)-stained core biopsy and clot sections, comprehensive immunophenotyping with flow cytometry (see next section on “Immunophenotyping”), and assessment of cytogenetic or molecular abnormalities. Identification of specific recurrent genetic abnormalities is critical for disease evaluation, optimal risk stratification, and treatment planning (see “Cytogenetic and Molecular Subtypes,” facing page). Subtypes of B-cell ALL with recurrent genetic abnormalities include the following: hyperdiploidy (DNA index > 1.16; 51–65 chromosomes); hypodiploidy (< 46 chromosomes); t(9;22)(q34;q11.2), BCR-ABL1; t(v;11q23), MLL rearrangement; t(12;21)(p13;q22), TEL-AML1; t(1;19)(q23;p13.3), E2A-PBX1; and t(5;14)(q31;q32), IL3-IGH. Presence of recurrent genetic abnormalities should be evaluated using karyotyping of G-banded metaphase chromosomes (conventional cytogenetics) and/or through interphase fluorescence in situ hybridization (FISH) assays that include probes capable of detecting the genetic abnormalities.

Immunophenotyping

Immunophenotypic classification of ALL involves the use of flow cytometry to determine the presence of cell surface antigens on lymphocytes. ALL can be classified broadly into 3 distinct groups based on immunophenotyping, which include precursor-B-cell ALL, mature B-cell ALL, and T-cell ALL. Among children, B-cell lineage ALL constitutes approximately 88% of cases; in adult patients, subtypes of B-cell lineage ALL constitute approximately 75% of cases (including mature B-cell ALL constituting 5% of adult ALL), whereas the remaining 25% constitute T-cell lineage ALL. Within the B-cell lineage, the profile of cell surface markers differ according to...
different stages of B-cell maturation. Pre-pre-B-cell (pro-B-cell) ALL is characterized by the presence of terminal deoxynucleotidyl transferase (TdT) and expression of CD19/CD22/CD79a, while being negative for CD10 (formerly referred to as common ALL antigen) or surface immunoglobulins; common B-cell ALL is associated with the expression of CD10; and pre-B-cell ALL is characterized by the presence of cytoplasmic immunoglobulins and CD10/CD19/CD22/CD79a expression.\(^\text{1,18,19,22}\) Mature B-cell ALL shows positivity for surface immunoglobulins and clonal lambda or kappa light chains, and is negative for TdT.\(^\text{1}\) In addition, CD20 may be expressed in approximately 50% of B-cell lineage ALL in adults, with a higher frequency (> 80%) observed in cases of mature B-cell ALL.\(^\text{23,24}\)

T-cell lineage ALL is typically associated with the presence of cytoplasmic CD3 (T-cell lineage blasts) or cell surface CD3 (mature T cells) in addition to CD1a/CD2/CD5/CD7 (variable expression for these markers) and TdT.\(^\text{1,18,20}\) Additionally, CD52 may be expressed in 30% to 50% of T-cell lineage ALL in adults.\(^\text{1}\) Early precursor T-cell ALL may represent a distinct biologic subtype of T-cell lineage ALL, and is associated with poor clinical outcomes even with contemporary treatment regimens; this subtype is characterized by the absence of CD1a/CD8, weak expression of CD5 (< 75% positive lymphoblasts), and presence of 1 or more myeloid or stem cell markers on at least 25% of lymphoblasts.\(^\text{25}\)

Hematologic malignancies related to ALL include acute leukemias with ambiguous lineage, such as the mixed phenotype acute leukemias (MPAL). MPAL include bilineage leukemias, in which 2 distinct populations of lymphoblasts are identified, with 1 meeting the criteria for acute myeloid leukemia. Another type of MPAL is the biphenotypic type, in which a single population of lymphoblasts express markers consistent with B-cell or T-cell ALL, in addition to expressing myeloid or monocytic markers. Notably, myeloid-associated markers such as CD13 and CD33 may be expressed in ALL, and the presence of these markers does not exclude this diagnosis.\(^\text{19,20}\) The identification of mixed lineage leukemias should follow the criteria presented in the 2008 WHO classification of neoplasms. The initial immunophenotyping panel should be sufficiently comprehensive to establish a leukemia-associated phenotype that may include expression of nonlineage antigens; these are useful in classification, particularly for MPAL.

**Cytogenetic and Molecular Subtypes**

Recurrent chromosomal and molecular abnormalities characterize ALL subtypes in both adults and children (Table 1), and often provide prognostic information that may weigh into risk stratification and treatment decisions. The frequency of certain subtypes differ between adult and childhood ALL, which partially explains the difference in clinical outcomes between patient populations. Among children with ALL, the most common chromosomal abnormality is hyperdiploidy (> 50 chromosomes; 25% of cases) seen in B-cell lineage ALL.\(^\text{16,26}\) The TEL-AML1 subtype (also within the B-cell lineage) resulting from chromosomal translocation t(12;21) is also among the most commonly occurring subtypes (22%) in childhood ALL.\(^\text{16}\) Both hyperdiploidy and TEL-AML1 subtypes are associated with favorable outcomes in ALL.\(^\text{26,27}\) Ph-positive ALL, associated with poor prognosis, is relatively uncommon among childhood ALL (3%), whereas this abnormality is the most common subtype among adults (25%).\(^\text{16}\) The frequency of Ph-positive ALL increases with age (e.g., 40% in patients > 50 years of age).\(^\text{26–32}\) Moreover, younger children (1–9 years of age) with Ph-positive ALL have a better prognosis than adolescents with this subtype.\(^\text{31}\) Although not as common, subtypes associated with translocations in the MLL gene [in particular, cases with t(4;11) translocation] are known to have poor prognosis.\(^\text{17,21}\) Hypodiploidy is only observed in 1% to 2% of patients, and is also associated with poor prognosis.\(^\text{17,32}\)

**Workup**

The initial workup for patients with ALL should include a thorough medical history and physical examination, along with laboratory and imaging studies (where applicable). Laboratory studies include a CBC count with platelets and differential, blood chemistry profile, disseminated intravascular coagulation panel (that includes measurements for D-dimer, fibrinogen, prothrombin time [PT], and partial thromboplastin time), and tumor lysis syndrome (TLS) panel (that includes measurements for serum lactate dehydrogenase, uric acid, potassium, phosphates, and calcium). Procurement of cells should
be considered for purposes of future research (in accordance with institutional practices or policies). All male patients should be evaluated for testicular involvement of disease; testicular involvement is especially common in cases of T-cell ALL. In addition, for patients with T-cell ALL, CT scans of the chest are warranted. All patients should be evaluated for infections, including screening for active infections if febrile or for symptomatic opportunistic infections. Empiric anti-infective therapy should be initiated, as appropriate (see NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections; to view the most recent version of these guidelines, visit NCCN.org). In addition, echocardiogram or cardiac scans should be considered for all patients given that anthracyclines are included in the backbone of nearly all treatment regimens. Assessment of cardiac function is particularly important for patients with prior cardiac history, prior anthracycline exposure, or clinical symptoms suggestive of cardiac dysfunction, and for elderly patients. Except in patients with major contraindications to hematopoietic stem cell transplantation (HSCT), HLA typing should be performed at workup. In patients with poor-risk features who lack a sibling donor, an early evaluation and search for alternative donors should be considered.

For patients with major neurologic signs or symptoms at diagnosis, appropriate imaging studies (e.g., CT/MRI scan of the head) should be performed to detect meningeal disease, chloromas, or central nervous system (CNS) bleeding. CNS involvement should be evaluated through lumbar puncture at the appropriate timing that is consistent with the treatment protocol being used. Pediatric-inspired regimens typically include lumbar puncture at diagnostic workup; however, the NCCN ALL Panel recommends that lumbar puncture, if performed, be done concomitantly with initial intrathecal therapy (see “NCCN Recommendations for Evaluation and Treatment of Extramedullary Involvement,” pages 871 and 898).

Prognostic Factors and Risk Stratification
Various disease-related and patient-specific factors may have prognostic significance in patients with ALL. In particular, patient age, WBC count, immunophenotypic/cytogenetic subtype, and response to induction therapy have been identified as important factors in defining risks and assessing prognosis for both adult and childhood ALL.

Prognostic Factors in AYA Patients With ALL
For childhood ALL, the initial risk assessment criteria established by the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG; the POG and CCG have since merged to form the Children’s Oncology Group [COG]) were based on age and initial WBC count for precursor B-cell ALL; T-cell ALL was considered high risk, or risk could be assessed based on age and WBC count for these patients. Subsequent risk assessment strategy assigned precursor B-cell ALL
cases in patients aged 1 to older than 10 years of age and WBC count less than $50 \times 10^9/L$ as “standard risk,” whereas all others, including T-cell ALL (regardless of age or WBC count), were considered “high risk.”“Very high risk” was defined as patients with any of the following characteristics: t(9;22) chromosomal translocation (i.e., Ph-positive ALL) and/or presence of BCR-ABL fusion protein, hypodiploidy (<44 chromosomes), or failure to achieve remission with induction therapy. Lastly, “lower risk” was defined for patients with either the t(12;21) chromosomal translocation leading to the TEL-AML1 subtype or simultaneous trisomies of chromosomes 4, 10, and 17.

Variability exists across studies with regard to the age ranges defined for AYA patients. The NCI defines the age range as 15 to 39 years. This definition has been adopted for the AYA sections of these guidelines. Historically, the AYA population has been treated on either a pediatric or an adult ALL regimen, depending on referral patterns and institution. However, studies in the past have shown poorer outcomes among patients in the AYA group compared with children younger than 10 years. The AYA patient population generally presents with lower frequency of favorable chromosomal/cytogenetic abnormalities, such as hyperdiploidy or TEL-AML1; increased frequency of T-cell immunophenotype; and slightly higher incidence of Ph-positive ALL, compared with younger children. In recent years, several retrospective studies from both the United States and Europe have shown that AYA patients (15–21 years of age) treated on a pediatric protocol have substantially improved event-free survival (EFS) outcomes than same-aged patients treated on adult ALL regimens. Thus, the choice of initial treatment regimen can have a profound impact on overall clinical outcomes in AYA patients.

**Prognostic Factors in Adults With ALL**

Both age and initial WBC count have historically been considered clinically significant prognostic factors in the management of adult patients with ALL. Early prospective multicenter studies showed that older age (>35 years) and higher initial WBC count (> $30 \times 10^9/L$) were significantly predictive of decreased remission duration. Subsequent studies have confirmed the prognostic importance of these clinical parameters, although the cutoff values differed between studies.

In one of the largest studies to date (N = 1521) conducted by the Medical Research Council (MRC) UKALL/ECOG, both age (>35 years) and WBC count (> $30 \times 10^9/L$ for B-cell lineage; > $100 \times 10^9/L$ for T-cell lineage) were found to be significant independent prognostic factors for decreased disease-free survival (DFS) and overall survival (OS) among patients with Ph-negative ALL; the independent prognostic value remained significant when these factors were evaluated as continuous variables in multivariate analysis. All patients, regardless of Ph status, had received induction therapy followed by intensification (for patients with a complete remission [CR] postinduction) with contemporary chemotherapy combination regimens. Patients with a CR after induction received allogeneic HSCT (for patients <50 years old and with HLA-compatible siblings), autologous HSCT, or consolidation/maintenance treatment. Because Ph-positive ALL is associated with very poor prognosis, patients with this subtype were assigned to undergo allogeneic HSCT (including matched unrelated donor HSCT), when possible. The 5-year OS rate among patients with Ph-positive and Ph-negative disease was 25% and 41%, respectively. Among the patients with Ph-negative ALL, those older than 35 years or with elevated WBC count (> $30 \times 10^9/L$ for B-cell lineage; > $100 \times 10^9/L$ for T-cell lineage) at diagnosis were initially identified as high risk, whereas all others were classified as having standard risk. The 5-year OS rates for the Ph-negative high-risk and standard-risk subgroups were 29% and 54%, respectively. Further analysis of the Ph-negative population according to risk factors showed that patients could be categorized as low risk (no risk factors based on age or WBC count), intermediate risk (either age > 35 years or elevated WBC count), or high risk (both age > 35 years and elevated WBC count). The 5-year OS rates based on these risk categories were 55%, 34%, and 5%, respectively, suggesting that Ph-negative patients in the high-risk subgroup had even poorer survival outcomes than those in the overall Ph-positive subgroup.

In a subsequent analysis from this MRC UKALL XII/ECOG 2993 study, cytogenetic data were evaluated in approximately 1000 patients. The analysis confirmed the negative prognostic impact of Ph-positive status compared with Ph-negative disease, with a significantly decreased 5-year EFS rate (16% vs. 36%; P < .001, adjusted for age, gender, and WBC count) and OS rate (22% vs. 41%; P < .001, adjusted for age, gender, and WBC count). Among patients
Acute Lymphoblastic Leukemia

with Ph-negative disease, the following cytogenetic subgroups had significantly decreased 5-year EFS (13%–24%) and OS rates (13%–28%) based on univariate analysis: t(4;11) MLL translocation; t(8;14); complex karyotype (≥ 5 chromosomal abnormalities); and low hypodiploidy (30–39 chromosomes)/near triploidy (60–78 chromosomes). In contrast, del(9p) or high hyperdiploidy (51–65 chromosomes) was associated with more favorable 5-year EFS (49%–50%) and OS rates (53%–58%).

Cases with 60 to 65 chromosomes were examined individually to determine the pattern of chromosomal gain that most closely resembled either hypodiploidy/triploidy or high hyperdiploidy. Based on multivariate Cox regression analysis, t(8;14), low hypodiploidy/near triploidy, and complex karyotype remained significant independent predictors for risk of relapse or death; the prognostic impact of these cytogenetic markers was independent of factors such as age, WBC count, or T-cell immunophenotype, and their significance was retained even after excluding patients who had undergone postinduction HSCT.

The importance of cytogenetics as a prognostic factor for survival outcomes was shown in other studies, including the SWOG study conducted in 200 adult patients with ALL. In this study, the prognostic impact of the different cytogenetic categories outweighed that of the more traditional factors, such as age and WBC count; in multivariate analysis for both relapse-free survival and OS, cytogenetics remained a significant independent predictor of outcomes, whereas factors such as age and WBC count lost prognostic significance. Moreover, the subgroup (n = 19) of patients with “very high risk” cytogenetic features (identified based on outcomes from the MRC/ECOG study mentioned earlier: presence of t(4;11) MLL translocation, t(8;14), complex karyotype, or low hypodiploidy/near triploidy) had substantially decreased 5-year relapse-free and OS rates (22%, for both end points). The 5-year relapse-free and OS rates among patients with Ph-positive ALL (n = 36) were 0% and 8%, respectively.

NCCN Recommendations for Risk Assessment in ALL

Although some debate remains in the risk stratification approach to ALL, the panel suggests the following approaches for defining risk in these patients.

Because AYA patients (defined as age 15–39 years) may benefit from pediatric-inspired ALL treatment protocols, this patient population is considered separately from the adult population (defined as age ≥ 40 years). Given the poor prognosis associated with Ph-positive ALL and the wide availability of agents that specifically target the BCR-ABL kinase, initial risk stratification for all patients (AYA or adult) is based on the presence or absence of the t(9;22) chromosomal translocation and/or BCR-ABL fusion protein.

AYA patients with Ph-negative ALL can be further categorized as having high-risk disease, which may be particularly helpful when consolidation therapy with allogeneic HSCT is being considered. High risk is defined as having any of the following poor-risk factors: elevated WBC count (≥ 30 × 10⁹/L for B-cell lineage; ≥ 100 × 10⁹/L for T-cell lineage); hypodiploidy; and MLL rearrangements. The absence of all of these poor-risk factors is considered standard risk.

For adult patients with ALL (Ph-positive or Ph-negative), these guidelines further stratify patients by age, using 65 years as the cutoff, to guide treatment decisions. However, chronologic age alone is a poor surrogate for determining patient fitness for therapy. Patients should therefore be evaluated on an individual basis.

For adult patients with Ph-negative ALL who are younger than 65 years (or for those with no substantial comorbidities), further risk stratification can be used to categorize patients as having high-risk disease. As with AYA patients, high risk is defined as having any of the following poor-risk factors: elevated WBC count (≥ 30 × 10⁹/L for B-cell lineage; ≥ 100 × 10⁹/L for T-cell lineage), hypodiploidy, and MLL rearrangements. However, data showing the effect of WBC counts on prognosis in adult patients with ALL are less firmly established than in the pediatric population. The absence of all of the described poor-risk factors is considered standard risk. These additional risk stratification parameters are generally not used for patients aged 65 years or older (or for patients with substantial comorbid conditions) with Ph-negative ALL.

Overview of Treatment Phases in ALL Management

The treatment approach to ALL represents one of the most complex and intensive programs in cancer therapy. Although the specific treatment regimens and selection of drugs, dose schedules, and treatment

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 10 Number 7 | July 2012
Induction

The intent of initial induction therapy is to reduce tumor burden by clearing as many leukemic cells as possible from the bone marrow. Induction regimens are typically based on a backbone that includes a combination of vincristine, anthracyclines (e.g., daunorubicin, doxorubicin), and corticosteroids (e.g., prednisone, dexamethasone) with or without L-asparaginase and/or cyclophosphamide. In addition, antimetabolites, such as methotrexate, cytarabine, and/or mercaptopurine, are often included at induction therapy, primarily for CNS prophylaxis (see next section).

The BFM/COG regimens are mainly based on a 4-drug induction regimen that includes a combination of vincristine, an anthracycline (e.g., daunorubicin, doxorubicin), and a corticosteroid (e.g., prednisone, dexamethasone) with or without L-asparaginase and/or cyclophosphamide. The CALGB regimens are typically based on a 5-drug regimen, which adds cyclophosphamide to the above 4-drug combination. Randomized studies comparing the use of dexamethasone versus prednisone as part of induction therapy may, at least partly, be attributed to improved penetration of dexamethasone in the CNS.

CNS Prophylaxis and Treatment

The goal of CNS prophylaxis and/or treatment is to eliminate potential leukemic cells that remain after induction therapy, including further eradication of refractory or relapsed leukemia, or second malignancy; risk ratio [RR], 0.80; 95% CI, 0.68–0.94) and CNS relapse (RR, 0.53; 95% CI, 0.44–0.65). However, no advantage was seen with a dexamethasone regimen compared with bone marrow relapse (RR, 0.90; 95% CI, 0.69–1.18) or overall mortality (RR, 0.91; 95% CI, 0.76–1.09), and dexamethasone was associated with a significantly higher risk of mortality during induction therapy (RR, 2.31; 95% CI, 1.46–3.66), neuropsychiatric adverse events (RR, 4.55; 95% CI, 2.45–8.46), and myopathy (RR, 7.05; 95% CI, 3.00–16.58) compared with prednisone. Thus, although dexamethasone seems beneficial in terms of reduced risks for CNS relapse and improved EFS, toxicities may be of concern, and an advantage for OS has yet to be conclusively shown.

The hyper-CVAD regimen may be considered a less complex treatment regimen compared with CALGB regimens, and comprises 8 cycles of alternating treatment cycles with the “A” regimen (hyper-CVAD: hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and “B” regimen (high-dose methotrexate and cytarabine). CNS prophylaxis and/or CNS-directed treatment (which may include cranial irradiation for patients with CNS leukemia at diagnosis), and maintenance treatment (as discussed on page 882) are also used along with the hyper-CVAD regimen.

Consolidation

The intent of postinduction consolidation is to eliminate potential leukemic cells that remain after induction therapy, including further eradication of re-
sidual disease. The postremission induction phase of treatment (but before long-term maintenance therapy) may also be described as intensification therapy. The combination of drugs and duration of therapy for consolidation regimens vary largely among studies and patient populations but can comprise combinations of drugs similar to those used during the induction phase. High-dose methotrexate, cytarabine, mercaptopurine, and L-asparaginase are frequently incorporated as part of consolidation/intensification regimens, particularly for regimens geared toward children with ALL.9,18,23,27,42,43

**Maintenance**

The goal of extended maintenance therapy is to prevent disease relapse after postremission induction and consolidation therapy. Most maintenance regimens are based on a backbone of daily mercaptopurine and weekly methotrexate (typically with the addition of periodic vincristine and corticosteroids) for 2 years in adults and 2 to 3 years in children.9,17,23,27 Maintenance therapy is omitted for patients with mature B-cell ALL (see the NCCN Guidelines for Non-Hodgkin's Lymphoma: Burkitt Lymphoma; to view the most recent version of these guidelines, visit NCCN.org), given that long-term remissions are seen early with short courses of intensive therapy in these patients, with relapses rarely occurring beyond 12 months.9,50

**Targeted Agents**

During the past decade, the advent of novel agents targeted to specific genetic abnormalities, such as those associated with Ph-positive ALL, or to specific cell surface antigens, has contributed to improvements in outcomes in some subtypes of ALL. These agents include BCR-ABL selective tyrosine kinase inhibitors (TKIs) for Ph-positive ALL,51-58 and anti-CD20 monoclonal antibody (e.g., rituximab) for CD20-expressing B-cell lineage ALL (especially for mature B-cell ALL).39,60 In addition, nelarabine has been approved for the treatment of relapsed/refractory T-cell lineage ALL.51-63 These agents may be incorporated as part of frontline induction, consolidation, and/or maintenance regimens during the course of initial ALL therapy, and in relapsed/refractory disease settings.

**Management of Ph-Positive ALL**

**Initial Treatment in AYA Patients With Ph-Positive ALL**

Ph-positive ALL is rare in children with ALL, occurring in only approximately 3% of pediatric cases compared with 25% of adult cases.16 The frequency of Ph-positive ALL is slightly higher (5%–7% of cases) among AYA patients,41 although this subtype is still uncommon compared with its incidence in older adults. Nevertheless, for children and adolescents with Ph-positive disease, the prognosis is generally much poorer compared with patients with Ph-negative B-cell ALL. In a retrospective analysis of children with Ph-positive ALL treated between 1986 and 1996 (N = 326) with intensive chemotherapy regimens with or without allogeneic HSCT, the 5-year EFS (calculated from time of diagnosis) and OS rates were 28% and 40%, respectively, for the entire patient cohort.31 The 7-year EFS and OS rates were 25% and 36%, respectively. Even among the subgroup of patients considered to have a better prognosis (i.e., WBC count < 50 × 10^9/L and age < 10 years), the 5-year DFS rate (calculated from time of first CR) was only 49%.31 In the subgroup of patients who underwent allogeneic HSCT with an HLA-matched related donor (n = 38), significantly higher 5-year DFS (65% vs. 25%; P < .001) and OS rates (72% vs. 42%; P = .002) were observed than in patients who received only chemotherapy; this benefit with HSCT versus chemotherapy alone was not observed with autologous HSCT or with HSCT from matched unrelated donors.64 This study showed that allogeneic HSCT from a matched related donor offered improvements in outcomes over chemotherapy alone. In a subsequent analysis of outcomes in children with Ph-positive ALL treated more recently (1995–2005) but also without targeted TKIs, the 7-year EFS and OS rates were 32% and 45%, respectively.64 Outcomes with allogeneic HSCT from either matched related or unrelated donors appeared similar, and HSCT was shown to provide improved disease control over intensive chemotherapy alone.64 Although this recent analysis showed improvements in 7-year EFS rates, outcomes remain suboptimal in patients with Ph-positive ALL.

The emergence of targeted therapies for hematologic malignancies, including the treatment of Ph-positive disorders with TKIs, represents an
important advancement in ALL therapy. Imatinib mesylate is an inhibitor of BCR-ABL tyrosine kinase and is approved by the FDA for the treatment of adult patients with relapsed or refractory Ph-positive ALL. In phase II studies in adults with ALL, imatinib has shown efficacy as single-agent therapy in the relapsed/refractory and frontline settings, and in combination with chemotherapy regimens during initial induction, consolidation, and/or maintenance.

Although allogeneic HSCT has been considered the standard of care for AYA patients with Ph-positive ALL, its role has become less clear with the advent of BCR-ABL–targeted TKIs such as imatinib. Several studies evaluated the role of allogeneic HSCT in the era of imatinib and whether imatinib-based therapies provided an additional benefit to HSCT.

A single-center retrospective study in children and adolescents with Ph-positive ALL who underwent allogeneic HSCT (N = 37; age 1–16 years) compared outcomes between patients who received pre- and/or post-HSCT imatinib (n = 13) and those who did not receive imatinib (n = 24). The 3-year DFS (62% vs. 53%, respectively) and relapse rates (15% vs. 26%, respectively) were not significantly improved with the use of imatinib. Patients who received HSCT in first CR had significantly improved DFS rates (71% vs. 29%; P = .01) and lower relapse rates (16% vs. 36%; P = .05) than those who underwent HSCT in second CR or later.

A recent study from the Spanish Cooperative Group compared outcomes of children and adolescents (age 1–15 years) treated with intermediate-dose imatinib combined with intensive chemotherapy followed by allogeneic HSCT (n = 16; 94% proceeded to HSCT) versus those of historical controls who did not receive imatinib before allogeneic HSCT (n = 27; 63% proceeded to HSCT). The 3-year EFS rate was significantly higher in the imatinib group compared with the historical controls (79% vs. 30%; P = .01).

A phase II study at MDACC evaluated imatinib combined with the hyper-CVAD regimen in patients with previously untreated or minimally treated ALL (N = 54; median age, 51 years; range, 17–84 years); 14 patients underwent subsequent allogeneic HSCT. The 3-year OS rate with this regimen was 54%. Among the patients aged 40 years or younger (n = 16), a strong trend was observed for OS benefit with allogeneic HSCT (3-year OS rate, 90% vs. 33%; P = .05).

In a multicenter COG study (AALL-0031) of children and adolescents with high-risk ALL, the group of patients with Ph-positive ALL (N = 92; age 1–21 years) were treated with an intensive chemotherapy regimen combined with imatinib (340 mg/m^2/d; given during postremission induction therapy and maintenance). Among the cohort (n = 44) who received continuous imatinib exposure (280 consecutive days before maintenance initiation), the 3-year EFS rate was 80.5% (95% CI, 64.5%–89.8%). This outcome compared favorably with that of a historical population of patients with Ph-positive ALL (N = 120) treated on a POG protocol, which showed a 3-year EFS rate of only 35% (P < .0001). Moreover, the 3-year EFS rates were similar among the groups of patients who received chemotherapy combined with continuous imatinib (88%; n = 25) or allogeneic HSCT from a related donor (57%; n = 21) or unrelated donor (72%; n = 11). No major toxicities were found to be associated with the addition of imatinib to the intensive chemotherapy regimen.

**Initial Treatment in Adults With Ph-Positive ALL**

Historically, treatment outcomes for adult patients with Ph-positive ALL have been extremely poor. Before the era of targeted TKIs, the 3-year OS rate with chemotherapy regimens was generally less than 20%. Allogeneic HSCT, in the preimatinib era, resulted in some improvements over chemotherapy alone, with 2-year OS rates of 40% to 50% and 3-year OS rates of 36% to 44%. In the large international collaborative MRC UKALL XII/ECOG 2993 trial conducted in patients with previously untreated ALL, the subgroup with Ph-positive disease (n = 267; median age, 40 years; range, 15–60 years) was eligible for allogeneic HSCT if they were younger than 50 to 55 years and had a matched sibling or matched unrelated donor.

Among the Ph-positive patient cohort, postremission treatment included matched sibling allogeneic HSCT (n = 45), matched unrelated donor allogeneic HSCT (n = 31), and chemotherapy alone (n = 86). The 5-year OS rate according to postremission therapy was 44%, 36%, and 19%, respectively, and the 5-year EFS rate was 41%, 36%, and 9%, respectively. Both the OS and
EFS outcomes for patients who underwent allogeneic HSCT (related or unrelated) were significantly improved compared with those who received only chemotherapy. The incidence of transplant-related mortality was 27% with matched sibling allogeneic HSCT and 39% with matched unrelated donor HSCT. An intent-to-treat analysis of patients with a matched sibling donor versus those without a matched sibling donor showed no statistically significant difference in 5-year OS rate (34% vs. 25%, respectively).73

The incorporation of imatinib in the treatment regimen for Ph-positive ALL has led to substantial improvements in outcomes over chemotherapy alone.58,59,69 Numerous phase II studies have evaluated the efficacy of imatinib combined with chemotherapy regimens in previously untreated patients; these studies showed positive results with the combined regimen, particularly when treatment was followed by allogeneic HSCT.51,56,58,67–69,76

In the phase II study from GRAALL (GRAAPH-2003), patients with previously untreated Ph-positive ALL (N = 45; median age, 45 years; range, 16–59 years) received imatinib in combination with chemotherapy during either induction or consolidation therapy.51,68 Patients in CR with a donor received allogeneic HSCT (n = 22), whereas those with CR and good molecular response but without a donor were eligible for autologous HSCT (n = 10). After a median follow-up of 46 months, the 4-year OS rate was not significantly different for patients with a donor than for those without (55% vs. 54%). This lack of a benefit in the donor group likely reflected the favorable survival outcomes seen in patients without a donor but who underwent autologous HSCT. Among the patients who underwent allogeneic HSCT, the 4-year OS (55% vs. 25%; P = .05) and DFS rates (47% vs. 25%; P = not significant) were improved compared with the subgroup without HSCT; no significant differences in outcomes were observed between allogeneic and autologous HSCT.68 The 4-year relapse rate was 24% and the incidence of treatment-related mortality was 32%.

In the subgroup of patients with Ph-positive ALL (N = 94; median age, 47 years; range, 19–66 years) from the Northern Italy Leukemia Group study (NILG-09/00), outcomes were compared between patients who received chemotherapy with imatinib (n = 59) or without imatinib (n = 35), with or without subsequent HSCT (allogeneic or autologous).76 The patients who received imatinib (63% of eligible patients) had significantly higher 5-year OS (38% vs. 23%; P = .009) and DFS rates (39% vs. 25%; P = .005) compared with those who did not receive imatinib (39% of eligible patients) had significantly better outcomes after allogeneic HSCT.76 The 5-year OS rates by treatment type were 47% for allogeneic HSCT (n = 45), 67% for autologous HSCT (n = 9), 30% for imatinib without HSCT (n = 15), and 8% for no imatinib and no HSCT (n = 13); the corresponding treatment-related mortality rates were 17%, 0%, 36%, and 23%, respectively. The 5-year relapse rates were 43%, 33%, 87%, and 100%, respectively.76

In a phase II study from the Spanish Cooperative Group, patients with Ph-positive ALL (N = 30; median age, 42 years; range, 8–62 years; only 1 patient was < 15 years of age) were treated with intensive chemotherapy combined with imatinib, followed by HSCT and imatinib maintenance.77 Overall, 53% of patients proceeded to allogeneic HSCT and 17% received autologous HSCT. At a median follow-up of 4.1 years, the OS and DFS rates were 30%. The incidence of transplant-related mortality was 27%.77 Posttransplant maintenance with imatinib was not feasible in most patients, primarily because of transplant-related complications.

Imatinib combined with the hyper-CVAD regimen was evaluated in a phase II study in patients with previously untreated or minimally treated ALL (N = 54; median age, 51 years; range 17–84 years), with 14 patients undergoing subsequent allogeneic HSCT.69 The 3-year OS rate with this regimen was 54% overall. Among patients aged 60 years or younger, no statistically significant difference was observed in the 3-year OS rate between patients who received HSCT and those who did not (77% vs. 57%). This finding is in contrast to results for younger patients (age ≤ 40 years) who received HSCT.

Another phase II study from GRAALL (GRAAPH-2005) compared induction therapy with imatinib combined with vincristine and dexamethasone versus imatinib combined with hyper-CVAD in patients younger than 60 years with previously untreated Ph-positive ALL (N = 118; n = 83 evaluable; median age, 42 years).78 Eligible patients proceeded to HSCT (allogeneic or autologous) after induction/consolidation phases. In an early report from this
Acute Lymphoblastic Leukemia

study, 52 patients proceeded to HSCT (allogeneic, n = 41; autologous, n = 11). The estimated 2-year OS rate was 62%; no significant difference was observed between patients who received imatinib with vincristine and dexamethasone and those who received imatinib with hyper-CVAD (68% vs. 54%, respectively). The 2-year DFS rate was 43%, with no significant difference between induction arms (54% vs. 32%, respectively).

In a phase II study from the Japan Adult Leukemia Study Group (ALL-202), patients with Ph-positive ALL (N = 100) were treated with chemotherapy combined with imatinib administered during induction, consolidation, and maintenance phases. An early analysis (N = 80; median age, 48 years; range, 15–63 years) reported a 1-year OS rate of 73% among patients who underwent allogeneic HSCT, compared with 85% for those who did not. A subsequent analysis compared outcomes for the subgroup of patients who received allogeneic HSCT at first CR in this study (n = 51; median age, 38 years; range, 15–64 years) versus those for a historical cohort of patients who received allogeneic HSCT without prior imatinib (n = 122). The 3-year OS (65% vs. 44%; P = .015) and DFS rates (58% vs. 37%; P = .039) were significantly higher among patients treated with imatinib compared with the historical cohort; the 3-year nonrelapse mortality rate was similar between cohorts (21% vs. 28%, respectively).

Collectively, these studies suggest that incorporation of imatinib into the therapeutic regimen improves outcomes for adult patients with Ph-positive ALL, particularly when administered before allogeneic HSCT. However, no randomized controlled studies have yet been conducted to establish the role of imatinib in the frontline or HSCT settings. In addition, a proportion of patients with Ph-positive ALL are resistant to initial therapy with imatinib-containing regimens or may experience relapse after imatinib therapy; resistance to imatinib is attributed, at least partly, to the presence of point mutations within the ABL kinase domain. Moreover, CNS relapse has been reported in both patients responsive to imatinib therapy (isolated CNS relapse with CR in marrow) and those resistant. The concentration of imatinib in the cerebrospinal fluid (CSF) has been shown to be approximately 2 logs lower than that achieved in the blood, suggesting that this agent does not adequately penetrate the blood-brain barrier to ensure CNS coverage.

A study showed that among patients with ALL treated with imatinib and who did not receive routine prophylactic intrathecal therapy or cranial irradiation, 12% developed CNS leukemia. Patients who were imatinib-resistant and developed CNS disease rapidly died from progressive disease; conversely, imatinib-sensitive patients who developed isolated CNS relapse could be successfully treated with intrathecal therapy with or without cranial irradiation.

Dasatinib is a second-generation TKI that inhibits both the BCR-ABL kinase and SRC family kinase, the latter of which is thought to be involved in an alternative signaling pathway in imatinib-resistant ALL; moreover, dasatinib displayed a 325-fold increase in potency in inhibiting in vitro growth of cells with wild-type BCR-ABL compared with imatinib, and maintained activity against cells harboring imatinib-resistant ABL kinase domain mutations, with the exception of the T315I, V299L, and F317L mutations. In phase II and III dose-comparison studies, dasatinib showed activity in patients with relapsed or refractory ALL who could not tolerate or were resistant to imatinib. Additionally, dasatinib showed activity against CNS leukemia in preclinical in vivo models and in a small group of patients with Ph-positive ALL with CNS involvement. Thus, it seems that dasatinib may provide some benefit over imatinib in terms of increased potency in inhibiting signaling pathways, activity against various ABL kinase mutations, and greater penetration of the blood-brain barrier.

Recent studies have shown the promising activity of dasatinib when incorporated into frontline regimens for patients with ALL. In a phase II study from MDACC, dasatinib was combined with hyper-CVAD and subsequent maintenance therapy in patients with previously untreated Ph-positive ALL (N = 35; median age, 53 years; range, 21–79 years; 31% were older than 60 years); 4 of the patients received allogeneic HSCT at first CR. The 2-year OS and EFS rates were 64% and 57%, respectively. In a study from GIMEMA (LAL-1205), patients with Ph-positive ALL (N = 53 evaluable; median age, 54 years; range, 24–76.5 years) received induction therapy with dasatinib and prednisone. Postinduction therapy included no further therapy (n = 2), TKI only (n = 19), TKI combined with chemotherapy...
(n = 10) with or without autologous HSCT (n = 4), or allogeneic HSCT (n = 18). All patients experienced a CR after induction therapy. The median OS was 31 months and the median DFS (calculated from day +85) was 21.5 months. At 20 months, the OS and DFS rates were 69% and 51%, respectively. T315I mutation was detected in 12 of 17 patients who experienced relapse (71%).

The treatment of older patients with Ph-positive ALL may pose a challenge, because elderly patients or those with comorbidities may not tolerate aggressive regimens with multiagent chemotherapy combined with TKIs. Several studies have evaluated outcomes with imatinib induction, with or without concurrent corticosteroids, in the older adult population with Ph-positive ALL. In a study that randomly assigned older patients with Ph-positive ALL (N = 55; median age, 68 years; range, 54–79 years; 94.5% were aged 60 years older) to induction therapy with imatinib versus chemotherapy alone, followed by imatinib-containing consolidation therapy, the estimated 2-year OS rate was 42%; no significant difference was observed between induction treatment arms. The median OS was numerically higher (but not statistically significantly different) among patients who received imatinib induction compared with those randomized to chemotherapy induction (23.5 vs. 12 months). However, the incidence of severe adverse events was significantly lower with imatinib induction (39% vs. 90%; P = .005), which suggested that induction therapy with imatinib may be better tolerated than chemotherapy in older patients with Ph-positive ALL. In a small phase II study from GRAALL (AFR-09 study), older patients (age ≥ 55 years) with Ph-positive ALL (N = 29 evaluable; median age, 63 years) were treated with chemotherapy induction followed by a consolidation regimen with imatinib and methylprednisolone. The 1-year OS rate in this study was significantly higher compared with that for historical control patients who received the same induction therapy but did not receive imatinib as part of consolidation (66% vs. 43%; P = .005), and the median OS in this study population was longer than that of control patients (23 vs. 11 months, respectively). In addition, the 1-year relapse-free survival rate was significantly increased with the addition of imatinib (58% vs. 11%; P < .001). A phase II study by GIMEMA (LAL0201-B study) also evaluated imatinib combined with corticosteroids in older patients (age > 60 years) with Ph-positive ALL (N = 29 evaluable; median age, 69 years). Patients received imatinib in combination with prednisone for induction. The estimated 1-year OS and DFS rates were 74% and 48%, respectively; the median OS was 20 months.

Treatment of Relapsed Ph-Positive ALL

The treatment of patients who experience relapse after initial therapy for ALL remains a challenge, because these patients have very poor prognosis. Several large studies have reported a median OS of only 4.5 to 6 months, and a 5-year OS rate of 3% to 10% among patients who experience relapse after initial treatment. One of the major factors associated with poorer survival outcomes after salvage therapy for relapsed ALL is the duration of response to frontline treatment. In an analysis of data from patients who experienced relapse in the PATHEMA trials, those who relapsed more than 2 years after frontline therapy had significantly higher 5-year OS rates than the groups of patients who did within 1 to 2 years or within 1 year of frontline therapy (31% vs. 15% vs. 2%, respectively; P < .001). Similarly, in the analysis of the group of patients who experienced relapse after frontline therapy in the MRC UKALL XII/ECOG 2993 trial, those who relapsed more than 2 years after initial diagnosis had a significantly higher 5-year OS rate than those who did within 2 years (11% vs. 5%; P < .001). In the pre-imatinib era, patients with Ph-positive ALL who experienced relapse after frontline therapy also had dismal outcomes; subgroup data from the large, prospective trials LALA-94 and MRC UKALL XII/ECOG 2993 showed a median OS of 5 months and a 5-year OS rate of 3% to 6% among patients subsequently treated for relapsed Ph-positive ALL.

The incorporation of TKIs such as imatinib in the frontline treatment regimen for Ph-positive ALL has become the established standard of care. However, the emergence of resistance to TKI therapy poses a challenge for patients who are primary refractory to or who experience relapse after initial treatment with TKI-containing regimens. Point mutations within the ABL kinase domain and alternative signaling pathways mediated by the SRC family kinase have been implicated in the mechanisms of resistance to imatinib. Mutations within the ABL kinase domain have been identified in a large proportion of patients who experi-
ence disease recurrence after imatinib-containing therapy.\textsuperscript{82,81} Moreover, ABL kinase domain mutations may be present in a small group of imatinib-naive patients even before initiation of any TKI therapy.\textsuperscript{101,102} Dasatinib and nilotinib are second-generation TKIs that have shown greater potency in inhibiting BCR-ABL compared with imatinib, and retention of antileukemic activity in cells with certain imatinib-resistant ABL mutations.\textsuperscript{87–89,103,104} Both TKIs have been evaluated as single-agent therapy in patients with Ph-positive ALL resistant to or intolerant of imatinib treatment.\textsuperscript{52,90,105,106} A randomized phase III study examined the activity of dasatinib administered as once-daily (140 mg daily) versus twice-daily dosing (70 mg twice daily) in patients with Ph-positive leukemia resistant to imatinib.\textsuperscript{90} In the group of patients with Ph-positive ALL (n = 84), the once-daily dosing resulted in higher response rates (major cytogenetic response) than the twice-daily dosing (70% vs. 52%), and although the median OS was shorter with the once-daily dosing (6.5 vs. 9 months), the median progression-free survival was longer (4 vs. 3 months) compared with twice-daily dosing.\textsuperscript{90} These differences in outcomes between the dosing arms were not statistically significant. Dasatinib is currently approved in the United States for the treatment of patients with Ph-positive ALL who are intolerant or resistant to prior therapy.

Not all imatinib-resistant ABL mutations are susceptible to the newer TKIs, however. For instance, dasatinib is not as active against cells harboring the ABL mutations T315I, V299L, and F317L.\textsuperscript{82,87–89,107–109} Thus, for patients who show resistance to TKI therapy, it becomes important to identify potential ABL mutations that may underlie the observed resistance to treatment. A panel of experts from the European LeukemiaNet recently published recommendations for the analysis of ABL kinase domain mutations in patients with chronic myelogenous leukemia, and treatment options according to the presence of different ABL mutations.\textsuperscript{110} Investigational TKIs, such as ponatinib and bosutinib, have shown promising activity in recent studies of patients with Ph-positive leukemias (including patients with ALL) resistant or intolerant to prior TKIs.\textsuperscript{111–113} For example, in an early analysis from the multicenter open-label phase II study (PACE trial; N = 403 enrolled), ponatinib showed substantial activity in patients with Ph-positive leukemias resistant or intolerant to second-generation TKIs, including in heavily pretreated patients with the ABL T315I gene mutation.\textsuperscript{111} Both ponatinib and bosutinib are currently investigational, and are not FDA-approved for any indication.

Treatment options are extremely limited for patients with Ph-positive ALL who experience relapse after receiving allogeneic HSCT. Several published cases have reported on the feasibility of inducing a molecular CR with dasatinib in patients with Ph-positive ALL who have experienced an early relapse after first allogeneic HSCT.\textsuperscript{114,115} The patients subsequently received a second allogeneic HSCT. The use of donor lymphocyte infusion (DLI) to induce further graft-versus-leukemia effect in patients experiencing relapse after allogeneic HSCT has been evaluated in several case reports and small studies. Several studies have reported little to no benefit of using DLI in patients with Ph-positive ALL who experience disease relapse after HSCT.\textsuperscript{116,117} These studies seemed to have administered DLI at hematologic relapse, when the leukemic tumor burden may have been too high to control effectively with DLI. Indeed, recent case reports have suggested that the use of DLI for residual disease or molecular relapse (as noted by levels of BCR-ABL fusion mRNA measured with polymerase chain reaction [PCR]) after allogeneic HSCT may eliminate residual leukemic clones and thereby prevent overt hematologic relapse.\textsuperscript{118–120} Moreover, case reports have also suggested using newer TKIs, such as dasatinib and nilotinib, along with DLI for managing relapse after allogeneic HSCT.\textsuperscript{121,122} Although these approaches are promising, data from prospective studies are needed to establish the role of DLI, with or without TKIs, in the treatment of relapse.

**NCCN Recommendations for Ph-Positive ALL**

**AYA Patients (Age 15–39 Years) With Ph-Positive ALL:** The panel recommends that AYA patients with Ph-positive ALL be treated on a clinical trial, when possible. In the absence of an appropriate clinical trial, the recommended induction therapy would comprise multiagent chemotherapy combined with a TKI. Treatment regimens should include adequate CNS prophylaxis for all patients. It is also important to adhere to the treatment regimens for a given protocol in its entirety, from induction therapy to consolidation/delayed intensification to maintenance therapy. For patients experiencing a CR after initial induc-
tion therapy, consolidation with allogeneic HSCT should be considered if a matched donor is available. However, in younger AYA patients (age ≤ 21 years), emerging data suggest that allogeneic HSCT may not confer an advantage over chemotherapy combined with TKIs. After HSCT, maintenance therapy (typically weekly methotrexate, daily 6-mercaptopurine, and monthly pulses of vincristine/prednisone for 2–3 years) with the addition of a TKI is recommended. For patients without a donor, consolidation therapy after a CR should comprise a continuation of multiagent chemotherapy combined with a TKI. These patients should continue to receive postconsolidation maintenance therapy with a regimen that includes a TKI. Individuals who inherit a nonfunctional variant allele of the gene encoding the enzyme thiopurine S-methyltransferase (TPMT) are known to be at high risk for developing hematopoietic toxicity (in particular, severe neutropenia) after treatment with mercaptopurine. Testing for TPMT gene polymorphism should be considered in patients receiving 6-mercaptopurine as part of maintenance therapy, particularly those who experience severe bone marrow toxicities.

The treatment approach for patients experiencing less than a CR after initial induction therapy (i.e., having primary refractory disease) would be similar to that for patients with relapsed/refractory ALL. Mutation testing for the ABL gene should be considered, because certain mutations may account for the observed resistance to induction therapy. For these patients with less than a CR to induction, a clinical trial with new investigational agents/ regimens would be preferred. In the absence of a suitable clinical trial, patients may be treated with multiagent chemotherapy combined with an alternative TKI (i.e., different from the TKI used as part of induction therapy). The choice of TKI would depend on the presence of specific ABL kinase domain mutations, because different mutation may confer greater resistance or susceptibility to particular TKIs. The panel has adopted the recommendations for treatment options based on ABL mutation status for CML, as recently published by the European LeukemiaNet. Based on these published recommendations, dasatinib (if not administered during initial induction) should be considered for patients with relapsed/refractory Ph-positive disease found to have the mutations Y253H, E255K/V, or F359V/C/I. For patients with relapsed/refractory disease found to have the mutations V299L, T315A, or F317L/V/I/C, nilotinib should be considered. Patients with the T315I mutation should be considered for allogeneic HSCT or participation in a clinical trial, if available, because this mutation is known to be resistant to currently available TKIs. For any other mutations of the ABL gene, either high-dose imatinib, dasatinib, or nilotinib may be considered. If a second CR is experienced with second-line treatment, the patient may be considered for allogeneic HSCT. Treatment with DLI is also an option if the patient has experienced relapse after allogeneic HSCT.

For patients with relapsed/refractory disease, participation on a clinical trial is preferred. In the absence of an appropriate trial, patients may be considered for second-line therapy with multiagent chemotherapy combined with an alternative TKI (i.e., different from the TKI used as part of induction therapy), allogeneic HSCT (if a second CR is experienced), or DLI (if the patient experienced relapse after allogeneic HSCT).

**Adult Patients (Age ≥ 40 Years) With Ph-Positive ALL:** For adult patients with Ph-positive ALL, the panel recommends treatment on a clinical trial, when possible. In the absence of an appropriate clinical trial, the recommended induction therapy would initially depend on the patient’s age and/or presence of comorbid conditions. Treatment regimens should include adequate CNS prophylaxis for all patients, and a given treatment protocol should be followed in its entirety, from induction therapy to consolidation/delayed intensification to maintenance therapy. Although the age cutoff indicated in the guidelines has been set at 65 years, it should be noted that chronologic age alone is not a sufficient surrogate for defining fitness; patients should be evaluated on an individual basis to determine fitness for therapy based on factors such as performance status, end organ function, and end organ reserve.

For relatively fit patients (age < 65 years or with no substantial comorbidities), the recommended treatment approach is similar to that of AYA patients. Induction therapy would comprise multiagent chemotherapy combined with a TKI. For patients experiencing a CR after induction, consolidation with allogeneic HSCT should be considered if a matched donor is available. After HSCT, maintenance therapy (typically involving weekly methotrexate, daily 6-mercaptopurine, and monthly
pulses of vincristine/prednisone for 2–3 years) with the addition of a TKI is recommended. For patients without a donor, consolidation therapy after a CR should comprise a continuation of multiagent chemotherapy combined with a TKI. These patients should continue to receive postconsolidation maintenance therapy with a regimen that includes a TKI. Again, testing for TPMT gene polymorphism should be considered for patients receiving 6-mercaptopurine as part of maintenance therapy, especially those who develop severe bone marrow toxicities after its initiation. For patients with less than a CR after induction, the treatment approach would be similar to that for patients with relapsed/refractory disease (see later discussion).

For patients who are less fit (age ≥ 65 years or with substantial comorbidities), the recommended induction therapy includes a TKI with corticosteroids or with chemotherapy regimens. Dose modifications may be required for chemotherapy agents, as needed. Patients with a CR to induction should continue consolidation therapy with a TKI with or without corticosteroids or a TKI with or without chemotherapy; maintenance therapy (typically weekly methotrexate, daily 6-mercaptopurine, and monthly pulses of vincristine/prednisone for 2–3 years) with the addition of a TKI is recommended. Patients with less than a CR after induction should be managed similar to those with relapsed/refractory disease.

For adult patients with relapsed/refractory disease, mutation testing for the ABL gene should be considered, and participation on a clinical trial with new investigational agents/regimens is suggested. In the absence of a suitable clinical trial, patients may be treated with an alternative TKI with or without corticosteroids or a TKI with or without chemotherapy, or may be considered for allogeneic HSCT (if a CR is experienced, and if the patient is sufficiently physically fit to undergo the procedure).

**Management of Ph-Negative ALL**

**Initial Treatment in AYAs With Ph-Negative ALL**

The AYA population with ALL can pose a unique challenge given that these patients may be treated with either a pediatric or an adult protocol, depending on local referral patterns and institutional practices. Retrospective analyses based on cooperative group studies from both the United States and Europe have consistently shown the superior outcomes for AYA patients (age 15–21 years) treated on pediatric versus adult ALL regimens. In the AYA population, 5-year EFS rates ranged from 63% to 74% for patients treated on a pediatric study protocol versus 34% to 49% for those receiving the adult protocol.\(^43,124–127\) In a recent retrospective comparative study that analyzed outcomes of AYA patients (age 16–20 years) treated on a pediatric CCG study protocol (n = 197; median age, 16 years) versus an adult CALGB study protocol (n = 124; median age, 19 years), the 7-year EFS rate was significantly improved for those treated on the pediatric regimen compared with those on the adult regimen (63% vs. 34%; \(P < .001\)); the 7-year OS rate was 67% versus 46%, respectively (\(P < .001\)).\(^41\) Moreover, AYA patients treated on the adult protocol experienced a significantly higher rate of isolated CNS relapse at 7 years (11% vs. 1%; \(P = .006\)). The substantial improvements in outcomes observed with the pediatric regimen in this study, and in the earlier retrospective analyses from other cooperative groups, may be attributed largely to its use of greater cumulative doses of drugs, such as corticosteroids (prednisone and/or dexamethasone), vincristine, and L-asparaginase, and to earlier, more frequent, and/or more intensive CNS-directed therapy compared with adult regimens.\(^43\)

Favorable outcomes with the use of pediatric-based treatment protocols in the AYA population have also been reported in other recent studies. In an analysis of outcomes in children and AYA patients treated in the Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols (1991–2000), the 5-year EFS rate among younger AYA patients (age 15–18 years; \(n = 51\)) was 78%, which was not significantly different from the EFS rates observed for children aged 10 to 15 years (77%; \(n = 108\)) or those aged 1 to 10 years (85%; \(n = 685\)).\(^128\) The CCG 1961 study was designed to evaluate the benefit of augmented versus standard postinduction intensification therapy in children aged 1 to 9 years with high WBC counts (≥ 50 × 10⁹/L) or in older children and adolescents aged 10 to 21 years.\(^4\) Patients were stratified by their initial response to induction therapy as either slow early responders (patients with > 25% bone marrow blasts on day 7 of induction) or rapid early responders. Among the patients who were rapid early responders to induction (N =
1299), the augmented postinduction intensity arm was associated with significantly increased rates of 5-year EFS (81% vs. 72%; \( P < .0001 \)) and OS (89% vs. 83%; \( P = .003 \)) compared with the standard-intensity arm.\( ^{42} \) In the subgroup of AYA patients (age 16–21 years; \( N = 262 \)) from the CCG 1961 study treated with either augmented or standard-intensity regimens, the 5-year EFS and OS rates were 71.5% and 77.5%, respectively.\( ^{129} \) Among the AYA patients who were considered rapid early responders, the augmented-intensity (\( n = 88 \)) and standard-intensity (\( n = 76 \)) arms showed no statistically significant differences in rates of 5-year EFS (82% vs. 67%, respectively) or OS (83% vs. 76%, respectively). For the AYA patients who were considered slow early responders (all of whom received the augmented-intensity regimen), the 5-year EFS rate was 71%.\( ^{129} \)

Data from the most recent Total Therapy (XV) study by the St. Jude Children’s Research Hospital also showed dramatic improvements in survival outcomes for the AYA population. In this study, patients were primarily risk-stratified based on treatment response; patients were treated according to risk-adjusted intensive chemotherapy, with the incorporation of minimal residual disease (MRD) evaluation during induction (day 19) to determine the need for additional doses of asparaginase.\( ^{130,131} \) The 5-year EFS rate for the AYA population (age 15–18 years; \( n = 45 \)) was 86% (95% CI, 72%–94%), which was not significantly different from the 87% EFS rate (95% CI, 84%–90%; \( P = .61 \)) observed for the younger patients (\( n = 448 \)). The 5-year OS rates for the AYA patients and younger patients were 88% and 94%, respectively (\( P = \text{not significant} \)).\( ^{130,131} \) The favorable EFS and OS outcomes in AYA patients in this study were attributed partly to the use of intensive dexamethasone, vincristine, and asparaginase, in addition to early intrathecal therapy (i.e., triple intrathecal chemotherapy with cytarabine, hydrocortisone, and methotrexate) for CNS-directed therapy. In addition, the use of prophylactic cranial irradiation was safely omitted in this study; the 5-year cumulative incidence of isolated CNS relapse and any CNS relapse was 3% and 4%, respectively, for the entire study population (\( N = 498 \)).\( ^{130} \) Moreover, all 11 patients with isolated CNS relapse were children younger than 12 years. This study showed that, with intensive risk-adjusted therapy and effective CNS-directed intrathecal regimens, AYA patients can obtain long-term EFS without the need for cranial irradiation or routine allogeneic HSCT.\( ^{130,131} \)

Given the success seen with multiagent intensive chemotherapy regimens for pediatric patients with ALL, several clinical trials have evaluated pediatric-inspired regimens for the AYA patient population. In one of these trials (PATHEMA ALL-96), adolescent (\( n = 35 \); age 15–18 years) and young adult (\( n = 46 \); age 19–30 years) patients with standard-risk Ph-negative ALL [defined as WBC count < 30 × 10\(^9\)/L; absence of t(9;22), t(1;19), t(4;14), or any other 11q23 rearrangements] received frontline therapy with a 5-drug induction regimen (vincristine, daunorubicin, prednisone, L-asparaginase, and cyclophosphamide), consolidation/reinduction, and maintenance, along with triple intrathecal therapy throughout the treatment period.\( ^{132} \) The 6-year EFS and OS rates for the entire patient cohort was 61% and 69%, respectively. No difference in EFS rate was observed between adolescents (60%; 95% CI, 43%–77%) and adults (63%; 95% CI, 48%–78%); similarly, no significant difference was observed in OS rate for adolescents (77%; 95% CI, 63%–91%) versus adults (63%; 95% CI, 46%–80%).\( ^{132} \) Based on multivariate regression analysis, slow response to induction therapy (defined as having > 10% blast cells in the bone marrow aspirate performed on day 14 of treatment) was the only factor associated with a poor EFS (odds ratio [OR], 2.99; 95% CI, 1.25–7.17) and OS (OR, 3.26; 95% CI, 1.22–8.70).\( ^{132} \)

A multicenter phase II trial evaluated a pediatric-inspired regimen (based on the DFCI Childhood ALL Consortium Protocol 00-01) in AYA and adult patients (age 16–50 years) with previously untreated ALL; 20% of the patients in this study were Ph-positive.\( ^{133} \) The treatment regimen comprised induction (vincristine, doxorubicin, prednisone, L-asparaginase, and high-dose methotrexate), triple intrathecal therapy, intensification, and maintenance. Among the 75 patients with evaluable data, the estimated 2-year EFS and OS rates were 72.5% and 77%, respectively.\( ^{133} \) Adverse events included 1 death from sepsis (during induction), pancreatitis in 9 patients (12%; including 1 death), osteonecrosis in 2 patients (3%), thrombosis/embolism in 14 patients (19%), and neutropenic infection in 23 patients (31%).\( ^{131} \) Although this intensive regimen was feasible in adult patients, further follow-up data are needed to evaluate long-term survival outcomes.
The prospective phase II GRAALL-2003 study evaluated a pediatric-inspired regimen (using intensified doses of vincristine, prednisone, and L-asparaginase) for adolescents and adults with Ph-negative ALL (N = 225; median age, 31 years; range, 15–60 years). The induction regimen comprised vincristine, daunorubicin, prednisone, L-asparaginase, and cyclophosphamide. Patients with high-risk disease and donor availability were allowed to proceed to allogeneic HSCT. The EFS and OS rates at 42 months were 55% and 60%, respectively. When data from patients who underwent transplantation at first CR were censored, the DFS rates at 42 months were 52% for high-risk patients and 68% for standard-risk patients (risk assignment based on GRAALL protocol); these DFS outcomes by risk groups were similar to outcomes using the MRC/ECOG definition for risk classification. Advanced age predicted for poorer survival outcomes on this study; the OS rate at 42 months was 41% for patients older than 45 years compared with 66% for those aged 45 years or younger. Moreover, advanced age (using 45 years as the cutoff) was associated with a higher cumulative incidence of therapy-related deaths (23% vs. 5%) and deaths in first CR (22% vs. 5%). Thus, it seems that the benefit of this pediatric-inspired regimen outweighed the risks for therapy-related deaths only for those patients up to 45 years of age with Ph-negative ALL.

A multicenter phase II Intergroup study (CALGB 10403) is currently ongoing to evaluate a pediatric-inspired regimen in the treatment of AYA patients with Ph-negative ALL up to 40 years of age (i.e., eligible patients are age 16–39 years). One of the objectives of this study is to compare the outcomes of patients treated on this trial with those of a similar group of patients (in regard to age and disease characteristics) treated by pediatric oncologists on the COG trial (AALL-0232). The treatment protocol includes a 4-drug induction regimen with intrathecal cytarabine and intrathecal methotrexate, consolidation, interim maintenance, delayed intensification, maintenance (for 2–3 years), and radiotherapy (for patients with testicular or CNS disease or those with T-cell ALL).

For patients with T-cell ALL, the addition of nelarabine may be a promising approach. Nelarabine is a nucleoside metabolic inhibitor and a prodrug of ara-G, approved for the treatment of patients with T-cell ALL who have not responded to or have experienced relapse after at least 2 chemotherapy regimens. This drug is currently under evaluation as part of frontline chemotherapy regimens in AYA patients with T-cell ALL. The initial safety results from the randomized phase III COG study (AALL-0434) of the augmented BFM chemotherapy regimen, with or without nelarabine, showed that the toxicity profiles were similar between patients with high-risk T-cell ALL who received nelarabine (n = 28) and those who did not (n = 29). No significant differences were observed in the occurrence of neurologic adverse events between these groups, including peripheral motor neuropathy, peripheral neuropathy, or CNS neurotoxicity. The incidence of adverse events such as febrile neutropenia and elevation of liver enzymes was also similar between treatment groups. These initial safety data suggest that nelarabine may be better tolerated in frontline regimens than in the relapsed/refractory setting. Results from the efficacy phase of this study are awaited.

For AYA patients in first CR, allogeneic HSCT may be considered for high-risk cases, such as those with elevated WBC counts and poor-risk cytogenetics (e.g., hypodiploidy, MLL rearrangement) at diagnosis. A large multicenter trial (LALQA-94 study) evaluated the role of postinduction HSCT as one of the study objectives in adolescent and adult ALL patients receiving therapy for previously untreated ALL (N = 922; median age, 33 years; range, 15–55 years). Patients were stratified into 4 risk groups: 1) Ph-negative standard-risk disease [defined as achievement of CR after 1 course of chemotherapy; absence of CNS disease; absence of t(4;11), t (1;19), or other 11q23 rearrangements; WBC count < 30 × 10^9/L]; 2) Ph-negative high-risk ALL (defined as patients with non–standard-risk disease and without CNS involvement); 3) Ph-positive ALL; and 4) evidence of CNS disease. After induction therapy, patients with Ph-negative high-risk ALL were eligible to undergo allogeneic HSCT if a matched sibling donor was available; those without a sibling donor were randomized to undergo autologous HSCT or chemotherapy alone. Among the subgroup of patients with Ph-negative high-risk ALL (n = 211), the median DFS and OS were 16 and 29 months, respectively. The 5-year DFS and OS rates were 30% and 38%, respectively. Based on intent-to-treat analysis, outcomes in patients with Ph-negative high-risk...
ALL were similar for autologous HSCT (n = 70) and chemotherapy alone (n = 59) in terms of median DFS (15 vs. 11 months), median OS (28 vs. 26 months), and 5-year OS rate (32% vs. 21%).

Outcomes were improved in patients with Ph-negative high-risk ALL and those with CNS involvement allocated to allogeneic HSCT. The median DFS was 21 months for these patients, and the median OS has not yet been reached; the 5-year OS rate was 51%. Thus, it appeared that in patients with Ph-negative high-risk disease, allogeneic HSCT in first CR improved DFS outcomes, whereas autologous HSCT did not result in significant benefit compared with chemotherapy alone.

In the PETHEMA ALL-93 trial, adult patients with high-risk ALL [defined as 30–50 years of age; WBC count ≥ 25 × 10⁹/L; or t(9;22), t(4;11), or other 11q rearrangements, or t(1;19)] received postremission induction therapy (N = 222 eligible; median age, 27 years; range, 15–50 years) with allogeneic HSCT (n = 84; if matched related donor available), autologous HSCT (n = 50), or chemotherapy alone (n = 48). Based on intent-to-treat analysis of data from Ph-negative high-risk patients, no significant advantage was observed in a donor versus no-donor comparison in terms of median DFS (21 vs. 38 months), median OS (32 vs. 67 months), 5-year DFS rate (37% vs. 46%), or 5-year OS rate (40% vs. 49%). In addition, when the analysis was conducted based on the actual postremission treatment received, no significant differences were noted between treatment arms for 5-year DFS rates (50% for allogeneic HSCT; 55% for autologous HSCT; 54% for chemotherapy alone).

The role of allogeneic HSCT in adults with ALL was also evaluated in the large multicenter MRC UKALL XII/ECOG 2993 study (N = 1913; age 15–59 years). In this study, high risk was defined as 35 years of age or older; time to CR of greater than 4 weeks from induction; elevated WBC counts (> 30 × 10⁹/L for B-cell ALL; > 100 × 10⁹/L for T-cell ALL); or the presence of Ph chromosome; all others were considered to be standard risk. Patients experiencing a remission with induction therapy were eligible to undergo allogeneic HSCT if a matched sibling donor was available or, in the absence of a sibling donor, were randomized to undergo autologous HSCT or chemotherapy. The 5-year OS rate was higher for patients randomized to chemotherapy alone compared with autologous HSCT (46% vs. 37%; P = .03). A donor versus no-donor comparison in all patients with Ph-negative ALL showed that the 5-year OS rate was significantly higher in the donor group than the no-donor group (53% vs. 45%; P = .01). This advantage in OS outcomes for the donor group was observed for patients with standard risk (62% vs. 52%; P = .02) but not for those with Ph-negative high-risk disease (41% vs. 35%). This was partly because of the high rate of nonrelapse mortality observed with the donor group compared with the no-donor group in patients with high-risk disease (36% vs. 14% at 2 years). Among patients with standard risk, the nonrelapse mortality rate at 2 years was 19.5% for the donor group and 7% for the no-donor group. Relapse rate was significantly lower in the donor group than the no-donor group for both patients with standard risk (24% vs. 49%; P < .001) and those with high risk (37% vs. 63%; P < .001). Nevertheless, the high nonrelapse mortality rate in the donor group among high-risk patients seemed to diminish the advantage of reduced risks for relapse in this group. This study suggested that allogeneic HSCT in first CR was beneficial in patients with standard-risk ALL.

The benefit of matched sibling allogeneic HSCT in adult patients with standard-risk ALL was also reported by the HOVON cooperative group. In a donor versus no-donor analysis of patients with standard-risk ALL undergoing postremission therapy with matched sibling allogeneic HSCT or autologous HSCT, the donor arm was associated with a significantly reduced 5-year relapse rate (24% vs. 55%; P < .001) and higher 5-year DFS rate (60% vs. 42%; P = .01) compared with the no-donor arm. In the donor group, the nonrelapse mortality rate at 5 years was 16% and the 5-year OS rate was 69%.

A recent systemic review and meta-analysis of published randomized trials on postremission induction therapy in adults with ALL reported a significant reduction in all-cause mortality with allogeneic HSCT in first CR (RR, 0.88; 95% CI, 0.80–0.97) compared with autologous HSCT or chemotherapy. A subgroup analysis showed a significant survival advantage with allogeneic HSCT in standard-risk ALL, whereas a nonsignificant advantage was seen in high-risk ALL. Autologous HSCT in first remission was not shown to be beneficial relative to chemotherapy, as shown by several large studies and meta-analyses.
Initial Treatment in Adults With Ph-Negative ALL

Typically, induction regimens for adult ALL are also based on a backbone of vincristine, corticosteroids, and anthracyclines. The CALGB 8811 trial evaluated a 5-drug induction regimen (comprising vincristine, daunorubicin, prednisone, L-asparaginase, and cyclophosphamide) as part of an intensive chemotherapy regimen for patients with previously untreated ALL (N = 197; Ph-positive in 29%; median age, 32 years; range, 16–80 years).\(^\text{11}\) The median OS for all patients was 36 months, after a median follow-up of 43 months. Among patients who experienced a CR (85% of all patients), the median remission duration was 29 months. The estimated 3-year OS rate was higher for the subgroup of patients younger than 30 years compared with those aged 30 to 59 years (69% vs. 39%). Among the subgroup of patients who were both Ph-negative and BCR-ABL–negative (n = 57), median OS was 39 months and the 3-year OS rate was 62%.\(^\text{11}\) Linker et al.\(^\text{12}\) evaluated an intensified chemotherapy regimen that incorporated a 4-drug induction regimen (comprising vincristine, daunorubicin, prednisone, and asparaginase) in adolescent and adult patients with ALL (N = 84; Ph-positive in 16%; median age, 27 years; range, 16–59 years). The 5-year EFS and OS rates for all patients were 48% and 47%, respectively. Among the patients who experienced a CR (93% of all patients), the 5-year EFS rate was 52%. Among the subgroup of patients without high-risk features (n = 53), the 5-year EFS rate was 60%.\(^\text{12}\)

In one of the largest multicenter prospective trials conducted to date (MRC UKALL XII/ECOG 2993 study), previously untreated adolescent and adult patients (N = 1521; age 15–59 years) received induction therapy comprising vincristine, daunorubicin, prednisone, and L-asparaginase for 4 weeks (phase I) followed by cyclophosphamide, cytarabine, oral 6-mercaptopurine, and intrathecal methotrexate for 4 weeks (phase II).\(^\text{13}\) After completion of induction therapy, patients who experienced a CR received intensification therapy with 3 cycles of high-dose methotrexate (with standard leucovorin rescue) and L-asparaginase. After intensification, those younger than 50 years who had an HLA-compatible sibling underwent allogeneic HSCT; all others were randomized to receive autologous HSCT or consolidation/maintenance treatment.\(^\text{13}\) For Ph-negative disease, high risk was defined as having any of the following factors: age of 35 years or older; time to CR greater than 4 weeks; or elevated WBC count (> 30 × 10\(^9\)/L for B-cell lineage; > 100 × 10\(^9\)/L for T-cell lineage). All other Ph-negative patients were considered to have standard-risk disease. The 5-year OS rate for all Ph-negative patients was 41%; the OS rate for the subgroups with standard risk (n = 533) and high risk (n = 590) was 54% and 29%, respectively.\(^\text{13}\) In the subgroup of patients with T-cell ALL (n = 356), the 5-year OS rate was 48%; the OS rate was improved to 61% for those with a matched sibling donor, primarily because of lower incidence of cumulative relapse.\(^\text{14}\) Among the patients with T-cell ALL, those with complex cytogenetic abnormalities had poor 5-year OS outcomes (19%).

The hyper-CVAD regimen constitutes another commonly used ALL treatment regimen for adult patients. A phase II study from MDACC evaluated hyper-CVAD in adolescents and adults with previously untreated ALL (N = 288; median age, 40 years; range, 15–92 years; Ph-positive in 17%).\(^\text{10}\) The median OS for all patients was 32 months and the 5-year OS rate was 38%, with a median follow-up of 63 months. Among patients who experienced a CR (92% of all patients), the 5-year CR duration rate was 38%.\(^\text{10}\) Death during induction therapy occurred in 5% of patients, and was more frequent among patients aged 60 years or older. Among the patients with Ph-negative ALL (n = 234), the 5-year OS rate was 42%.\(^\text{10}\)

Based on retrospective analyses of data from adults with B-cell ALL treated in clinical trials, CD20 positivity (generally defined as CD20 expression on > 20% of blasts) was found to be associated with adverse outcomes in terms of a higher cumulative incidence of relapse, decreased CR duration, or decreased survival.\(^\text{24,14}\)\(^3\)\(^4\)\(^5\)\(^6\)\(^7\)\(^8\)\(^9\)\(^10\) Given the prognostic significance of CD20 expression in these patients, treatment regimens incorporating the CD20 monoclonal antibody rituximab have been evaluated. A phase II study from MDACC evaluated hyper-CVAD with or without rituximab in previously untreated patients with Ph-negative B-lineage ALL (N = 282; median age, 41 years; range, 13–83 years).\(^\text{10}\) Among the subgroup of patients with CD20-positive ALL who were treated with hyper-CVAD combined with rituximab, the 3-year CR duration rate and OS rate was 67% and 61%, respectively. In addition, among the younger patients (age < 60 years) with CD20-
positive disease, modified hyper-CVAD plus rituximab resulted in significantly improved CR duration (70% vs. 38%; \( P < .001 \)) and OS rates (75% vs. 47%; \( P = .003 \)) compared with the standard hyper-CVAD regimen without rituximab.\(^{60} \) No significant differences in outcomes with the addition of rituximab were noted for the subgroup of patients who were CD20-negative. Notably, older patients (age \( \geq 60 \) years) with CD20-positive disease did not seem to benefit from the addition of rituximab, partly because of a high incidence of death in CR among older patients.

For discussion of HSCT in first CR in adult patients with Ph-negative ALL, refer to “Initial Treatment in AYAs With Ph-Negative ALL,” page 889.

**Treatment of Relapsed Ph-Negative ALL**

Despite major advances in the treatment of childhood ALL, approximately 20% of pediatric patients experience relapse after initial CR to frontline treatment regimens.\(^{6,7,144} \) Among those who experience relapse, only approximately 30% experience long-term remission with subsequent therapies.\(^{61,145,146} \) Based on a retrospective analysis of historical data from COG studies (for patients enrolled between 1998 and 2002; \( N = 9585 \)), early relapse (\(< 18 \) months from diagnosis) was associated with very poor outcomes, with an estimated 5-year survival (from time of relapse) of 21%.\(^{144} \) For cases of isolated bone marrow relapse, the 5-year survival estimates among early (\( n = 412 \)), intermediate (\( n = 324 \)), and late (\( n = 387 \)) relapsing patients were 11.5%, 18%, and 43.5%, respectively (\( P < .0001 \)). Intermediate relapse was defined as relapses occurring between 18 and 36 months from time of diagnosis; late cases were defined as relapses occurring 36 months or more from diagnosis. For cases of isolated CNS relapse, the 5-year survival estimates among early (\( n = 175 \)), intermediate (\( n = 180 \)), and late (\( n = 54 \)) relapsing patients were 43.5%, 68%, and 78%, respectively (\( P < .0001 \)).\(^{144} \) Based on multivariate analysis (adjusted for both timing and site of relapse), age (\( > 10 \) years), presence of CNS disease at diagnosis, male gender, and T-cell lineage disease were found to be significant independent predictors of decreased survival after relapse.\(^{144} \)

In a separate analysis of data from one of the COG studies (CCG-1952), the timing and site of first relapse was significantly predictive of EFS and OS outcomes, even among the patients with standard-risk ALL (\( N = 347 \); based on NCI criteria: age 1 to \(< 10 \) years of age and WBC count \(< 50 \times 10^9/L \)).\(^{147} \) Early bone marrow relapse (duration of first CR \(< 36 \) months) was associated with significantly shorter estimated 3-year EFS (30% vs. 44.5%; \( P = .002 \)) and OS (35% vs. 58%; \( P = .001 \)) compared with late bone marrow relapse.\(^{147} \) Similarly, early isolated extramedullary relapse (duration of first CR \(< 18 \) months) was associated with significantly shorter estimated 3-year EFS (37% vs. 71%; \( P = .01 \)) and OS (55% vs. 81.5%; \( P = .039 \)) compared with late extramedullary relapse. In a multivariate regression analysis, early bone marrow and extramedullary relapse were independent predictors of poorer EFS outcomes.\(^{147} \)

AYA and adult patients with ALL who experience relapse after initial therapy have extremely poor long-term outcomes. Based on data from patients with disease relapse after frontline therapy in the MRC UKALL XII/ECOG 2993 study and PETHERMA studies, the median OS after relapse was only 4.5 to 6 months; the 5-year OS rate was 7% to 10%.\(^{96,97} \) Approximately 20% to 30% of patients experience a second CR with salvage therapies.\(^{97,98} \) Factors predictive of more favorable outcomes after salvage therapies included younger age and a first CR duration of more than 2 years.\(^{75,97} \) Among younger patients (age \(< 30 \) years) whose disease relapsed after experiencing a first CR duration longer than 2 years with frontline treatment on PATHERMA trials, the 5-year OS rate from the time of first relapse was 38%.\(^{97} \)

The treatment of AYA and adult patients with relapsed and/or refractory ALL remains a challenge. Clofarabine is a nucleoside analog approved for the treatment of pediatric patients (age 1–21 years) with ALL relapsed or refractory after at least 2 prior regimens.\(^{148} \) In a phase II study of single-agent clofarabine in heavily pretreated pediatric patients with relapsed or refractory ALL (\( N = 61 \); median age, 12 years; range, 1–20 years; median 3 prior regimens), the response rate (CR + CR without platelet recovery [CRp]) was 20%.\(^{149} \) Among the responding patients, the median duration of remission was 29 weeks. The median OS for all patients was 13 weeks, and has not yet been reached among the patients with a CR; median OS was 54 weeks for patients with a CRp, and 30 weeks for patients with a partial remission.\(^{149} \) In a small phase II study evaluating the combination of clofarabine with cyclophosphamide and etoposide in pediatric patients with refractory or multiple relapsed
ALL (N = 25; median age, 12.5 years), the regimen resulted in a CR rate of 52% (plus an additional 4% CRp), with an 18-month OS probability of 39% among responders.\textsuperscript{150} Clofarabine has been shown to be active in combination with other chemotherapy in adults with relapsed/refractory disease. In a recent study from GRAALL, clofarabine in combination with conventional chemotherapy regimens yielded a CR rate of 44% in patients with relapsed/refractory ALL (N = 55); the median OS was 6.5 months after a short median follow-up of 6 months.\textsuperscript{151} Another alkylator-containing salvage regimen, comprising ifosfamide, etoposide and mitoxantrone, was evaluated in a small phase II study in adult patients with relapsed or refractory ALL (N = 11); 8 patients (73%) experienced a CR, and the median DFS and OS from time of remission were 3.1 and 7.7 months, respectively.\textsuperscript{152} The combination of high-dose cytarabine and idarubicin was evaluated as a salvage regimen in adult patients with relapsed/refractory ALL (N = 29).\textsuperscript{153} In this study, 11 patients (38%) experienced a CR, and the median OS for responding patients was 8 months. Four patients who experienced a CR with salvage therapy proceeded to allogeneic HSCT. The median OS for all patients on the study was 6 months.\textsuperscript{153}

A recent phase II study from MDACC evaluated an augmented hyper-CVAD regimen (that incorporated asparaginase, intensified vincristine, and intensified dexamethasone) as salvage therapy in adults with relapsed/refractory ALL (N = 90; median age, 34 years; range, 14–70 years; median 1 prior regimen).\textsuperscript{154} Among evaluable patients (n = 88), the CR rate was 47%; an additional 13% experienced a CRp and 5% a partial remission. The 30-day mortality rate was 9%, and was lower among the subgroup who received polyethylene glycol (PEG)-asparaginase than those who received L-asparaginase (1% vs. 12%). Median remission duration was 5 months. The median OS for all evaluable patients was 6.3 months; median OS was 10.2 months for patients who experienced a CR. In this study, 32% of patients were able to proceed to HSCT.\textsuperscript{154}

Nelarabine is a nucleoside analog that is currently approved for the treatment of patients with T-cell ALL who have not experienced response to or have relapsed after at least 2 chemotherapy regimens.\textsuperscript{155} A phase II study of nelarabine monotherapy in children and adolescents with relapsed/refractory T-cell ALL or T-cell non-Hodgkin lymphoma (N = 121) showed a 55% response rate among the subgroup with T-cell ALL with first bone marrow relapse (n = 34) and a 27% response rate in the subgroup with a second or greater bone marrow relapse (n = 36).\textsuperscript{61} Major toxicities with this agent included grade 3 or higher neurologic (both peripheral and CNS) adverse events in 18% of patients. Nelarabine as single agent was also evaluated in adults with relapsed/refractory T-cell ALL or T-cell lymphoblastic leukemia in a phase II study (N = 39; median age, 34 years; range, 16–66 years; median 2 prior regimens; T-cell ALL, n = 26).\textsuperscript{63} The CR rate (including CR with incomplete blood count recovery [CRi]) was 31%; an additional 10% of patients experienced a partial remission. The median DFS and OS were both 20 weeks. The 1-year OS rate was 28%. Grade 3 or 4 myelosuppression was common, but only 1 case of grade 4 CNS toxicity (reversible) was observed.\textsuperscript{63}

Novel monoclonal antibodies are currently under clinical investigation. Inotuzumab ozogamicin is an anti-CD22 antibody-drug conjugate that has shown high CR rates (57%) in a phase II study in patients with relapsed/refractory ALL (N = 49).\textsuperscript{155,156} Blinatumomab is a bispecific anti-CD3/CD19 monoclonal antibody that showed high CR rates (67%; including rapid MRD-negative responses) in patients with relapsed/refractory B-precursor ALL (N = 18).\textsuperscript{157} In an earlier study, blinatumomab was shown to eliminate residual disease in patients with relapsed or MRD-positive B-precursor ALL after intensive chemotherapy (N = 21).\textsuperscript{158} These antibodies are investigational and are not FDA-approved for any indication.

Based on findings from evidence-based review of the published literature, the American Society for Blood and Marrow Transplantation guidelines recommend HSCT over chemotherapy alone for adult patients with ALL experiencing a second CR.\textsuperscript{159} Several studies have shown that for AYA patients in second CR, allogeneic HSCT may improve outcomes, particularly for patients who have early bone marrow relapse or have other high-risk factors, such as T-cell ALL.\textsuperscript{145,146,160} In a retrospective analysis of children and adolescents (age 1–18 years) with precursor B-cell ALL experiencing a second CR after bone marrow relapse, outcomes were compared between patients who underwent allogeneic HSCT (n = 186) and those who received chemotherapy regimens on the POG trials (n = 188).\textsuperscript{160} The study showed that among patients with early bone mar-
row relapse (< 36 months from time of diagnosis), total body irradiation (TBI)–containing allogeneic HSCT was associated with significantly lower risks of a second relapse (relative risk, 0.49; 95% CI, 0.33–0.71; P < .001) or overall mortality (relative risk, 0.58; 95% CI, 0.41–0.83; P = .003) compared with chemotherapy regimens. This advantage with TBI-containing allogeneic HSCT was not observed among the subgroup with a late first relapse (≥ 36 months), and no advantages were seen with the use of non–TBI-containing HSCT regimens regardless of the timing of first relapse.160 Thus, among patients with precursor B-cell ALL in second CR after early bone marrow relapse, TBI-containing allogeneic HSCT may improve outcomes compared with chemotherapy alone; however, for patients with late bone marrow relapse, HSCT may offer no advantage over chemotherapy regimens.

A BFM study (BFM-87) evaluated long-term outcomes with intensive chemotherapy or HSCT (for poor prognosis disease) in patients with ALL relapsing after frontline treatment (N = 207; age up to 18 years).145 In this study, patients with poor prognosis included those having an early bone marrow relapse (defined as relapse occurring during therapy or up to 6 months after completion of frontline treatment) or T-cell ALL. The 15-year EFS and OS rates for the entire patient cohort were 30% and 37%, respectively.145 The 10-year EFS rate was significantly higher among the patients who received allogeneic HSCT after second CR (n = 27) compared with those who received chemotherapy/radiotherapy only (n = 145; 59% vs. 30%; P = .026). All recipients of allogeneic HSCT received TBI as part of the conditioning regimen. Based on multivariate regression analysis, the timing and site of relapse (with early relapse and isolated bone marrow relapse associated with poor outcomes), T-cell lineage disease, and HSCT were significant independent predictors of EFS outcomes.145

The more recent BFM study (BFM-90) in patients with ALL relapsing after frontline therapy (N = 525; age 1–18 years) further confirmed the benefits of allogeneic HSCT in second CR.146 In this study, the timing of first relapse was defined as very early (within 18 months from initial diagnosis), early (> 18 months from initial diagnosis and < 6 months after completion of frontline therapy), and late (> 6 months after completion of frontline treatment). The overall 10-year EFS and OS rates in this study were 30% and 36%, respectively.146 Among the patients with high-risk disease (i.e., having early isolated bone marrow relapse, early combined bone marrow and extramedullary relapse, very early bone marrow relapse, or T-cell lineage ALL regardless of relapse timing), patients who received chemotherapy alone had significantly shorter 10-year EFS (n = 76; 20%) than those who received HSCT (n = 84; 33% EFS rate; P < .005) or the subgroup of patients who received HLA-compatible allogeneic HSCT (n = 53; 40% EFS rate; P < .001). This EFS benefit with HSCT (or with allogeneic HSCT) was not observed among the subgroup of patients with intermediate-risk disease (i.e., late bone marrow relapse or isolated extramedullary relapse regardless of relapse timing). The preferred conditioning regimen for HSCT in this study included TBI.146

Somewhat contrastingly, the COG study CCG-1952 showed that prognosis after early bone marrow relapse remained poor in patients with standard-risk ALL (age 1 to < 10 years of age and WBC count < 50 × 10⁹/L); no apparent advantage with HSCT was observed, regardless of timing (e.g., early or late) of bone marrow relapse.147 For these patients with bone marrow relapse, no significant differences were observed in the EFS or OS rates between treatment with HSCT (n = 77) or chemotherapy (n = 81); the 2-year estimated EFS rates with HSCT and chemotherapy were 49.5% and 49%, respectively (P = .39). Moreover, no significant differences in EFS rates were observed in the subgroup of patients with early or late bone marrow relapses.147 However, data were not available on the conditioning regimen used for HSCT in this study.

NCCN Recommendations for Ph-Negative ALL

AYA Patients (Age 15–39 Years) With Ph-Negative ALL: The panel recommends that AYA patients with Ph-negative ALL (regardless of risk group) be treated on a clinical trial, where possible. In the absence of an appropriate clinical trial, the recommended induction therapy would comprise multiagent chemotherapy regimens based on pediatric-inspired protocols, such as the CCG-1961, PETHEMA ALL-96, GRAALL-2003, and COG AALL-0434 (for T-cell ALL) regimens or the ongoing CALGB 10403 protocol. Treatment regimens should include adequate CNS prophylaxis for all patients. It is also important to adhere to the treatment regimens for a given proto-
col in its entirety, from induction therapy to consolidation/delayed intensification to maintenance therapy. Testing for TPMT gene polymorphism should be considered for patients receiving 6-mercaptopurine as part of maintenance therapy, especially in those who experience severe bone marrow toxicities.

For patients experiencing a CR after initial induction therapy, monitoring for MRD may be considered (see “NCCN Recommendations for MRD Assessment,” page 903). In these patients, continuation of the multiagent chemotherapy protocol for consolidation and maintenance would be appropriate (particularly for patients with MRD-negative remission after induction, if MRD is assessed). If a matched donor is available, consolidation with allogeneic HSCT may also be considered, particularly for patients with residual disease as assessed with MRD assays, or for those with high-risk disease features (i.e., WBC count ≥ 30 × 10⁹/L for B-cell lineage; ≥ 100 × 10⁹/L for T-cell lineage, hypodiploidy, or MLL rearrangements). The benefit of allogeneic HSCT in the setting of MRD-positive remission is currently unclear. For AYA patients experiencing less than a CR after initial induction therapy (i.e., having primary refractory disease), the treatment approach would be similar to that for patients with relapsed/refractory ALL.

For patients with relapsed/refractory disease after an initial CR, the approach to second-line treatment may depend on the duration of the initial response. For late relapses (i.e., relapse occurring ≥ 36 months from initial diagnosis), re-treatment with the same induction regimen may be reasonable. Participation on a clinical trial is preferred, where possible. In the absence of an appropriate trial, the patient may be considered for second-line therapy with induction regimens not previously used, salvage chemotherapy (with regimens containing clofarabine, nelarabine [for T-cell ALL], cytarabine, or alkylating agents), or allogeneic HSCT (if a second CR is achieved).

**Adult Patients (Age ≥ 40 Years) With Ph-Negative ALL:** For adult patients with Ph-negative ALL, the panel also recommends treatment on a clinical trial, where possible. In the absence of an appropriate clinical trial, the recommended treatment approach would initially depend on the patient’s age and/or presence of comorbid conditions. Treatment regimens should include adequate CNS prophylaxis for all patients, and a given treatment protocol should be followed in its entirety, from induction therapy to consolidation/delayed intensification to maintenance therapy. Again, testing for TPMT gene polymorphism should be considered for patients receiving 6-mercaptopurine as part of maintenance therapy, especially in those who develop severe bone marrow toxicities.

Although the age cutoff indicated in the guidelines has been set at 65 years, it should be noted that chronicologic age alone is not a sufficient surrogate for defining fitness; patients should be evaluated on an individual basis to determine fitness for therapy based on factors such as performance status, end-organ function, and end-organ reserve.

For relatively fit patients (age < 65 years or with no substantial comorbidities), the recommended treatment approach is similar to that for AYA patients. Induction therapy would comprise multiagent chemotherapy such as those based on protocols from the CALGB 8811 study (Larson regimen), the Linker regimen, hyper-CVAD (with or without rituximab), or the MRC UKALL XII/ECOG 2993 study. For patients experiencing a CR after initial induction therapy, monitoring for MRD may be considered (see “NCCN Recommendations for MRD Assessment,” page 903). In these patients, continuation of the multiagent chemotherapy protocol for consolidation and maintenance would be appropriate (particularly for patients with MRD-negative remission after induction, if MRD is assessed). If a matched donor is available, consolidation with allogeneic HSCT may be considered for patients with residual disease as assessed with MRD assays, although the benefit of allogeneic HSCT in this setting is currently unclear. In addition, allogeneic HSCT may also be considered for relatively fit adult patients (age < 65 years or with no substantial comorbidities) with high-risk disease features (i.e., WBC count ≥ 30 × 10⁹/L for B-cell lineage; ≥ 100 × 10⁹/L for T-cell lineage, hypodiploidy, or MLL rearrangements).

The effect of WBC counts on prognosis in adult patients with ALL is less firmly established than in pediatric populations. For adult patients experiencing less than a CR after initial induction therapy, the treatment approach would be similar to that for patients with relapsed/refractory ALL (as discussed later).

For patients who are less fit (age ≥ 65 years or with substantial comorbidities), the recommended induction therapy includes multiagent chemother-
apy regimens or corticosteroids. Dose modifications may be required for chemotherapy agents, as needed. Patients with a CR to induction should continue consolidation with chemotherapy regimens; maintenance therapy (typically weekly methotrexate, daily 6-mercaptopurine, and monthly pulses of vincristine/prednisone for 2–3 years) is recommended. For patients with less than a CR to induction, the treatment option would be similar to that for patients with relapsed/refractory ALL.

For patients with relapsed/refractory disease after an initial CR, participation on a clinical trial is preferred, when possible. In the absence of an appropriate trial, patients may be considered for second-line therapy with induction regimens not previously used, salvage chemotherapy (with regimens containing clofarabine, naringene [for T-cell ALL], cytarabine, or alkylating agents), or allogeneic HSCT (if a second CR is experienced) in those physically fit enough to undergo transplantation.

For recommendations on the treatment of adult patients with mature B-cell ALL, refer to the NCCN Guidelines for NHL: Burkitt Lymphoma (to view the most recent version of these guidelines, visit NCCN.org).

**Evaluation and Treatment of Extramedullary Disease**

**CNS Involvement in ALL**

Although the presence of CNS involvement at diagnosis is uncommon (approximately 3%–7% of cases), a substantial proportion of patients (> 50%) will eventually develop CNS leukemia in the absence of CNS-directed therapy.\(^1,27\) CNS leukemia is defined by the presence of WBC 5/mcL or greater in the CSF with presence of lymphoblasts.\(^1,27\) In children with ALL, CNS leukemia at diagnosis was associated with significantly decreased EFS rates.\(^23,162\) Factors associated with increased risks for CNS leukemia in children include T-cell immunophenotype, high presenting WBC counts, Ph-positive disease, \(t(4;11)\) translocation, and presence of leukemic cells in the CSF.\(^163\) In adults with ALL, CNS leukemia at diagnosis has been associated with a significantly higher risk for CNS relapse in large trials, although no differences were observed in 5-year EFS or DFS rates compared with subgroups without CNS leukemia at presentation.\(^162,163\) CNS leukemia at diagnosis was associated with significantly decreased 5-year OS rate in one trial (29% vs. 38%; \(P = .03\))\(^162\) but not in another trial (35% vs. 31%).\(^162\) Factors associated with increased risks for CNS leukemia in adults include mature B-cell immunophenotype, T-cell immunophenotype, high presenting WBC counts, and elevated serum lactate dehydrogenase (LDH) levels.\(^23,162\) CNS-directed therapy may include cranial irradiation, intrathecal chemotherapy (e.g., methotrexate, cytarabine, corticosteroids), and/or high-dose systemic chemotherapy (e.g., methotrexate, cytarabine, mercaptopurine, L-asparaginase).\(^1,27,46\)

Although cranial irradiation is an effective treatment modality for CNS leukemia, it can be associated with serious adverse events, such as neurocognitive dysfunctions, secondary malignancies, and other long-term complications.\(^1,46\) With the increasing use of effective intrathecal chemotherapy and high-dose systemic chemotherapy regimens, studies have examined the feasibility of eliminating cranial irradiation as part of CNS prophylaxis. In studies of children with ALL who only received intrathecal and/or intensive systemic chemotherapy for CNS prophylaxis, the 5-year cumulative incidence of isolated CNS relapse or any CNS relapse was 3% to 4% and 4% to 5%, respectively.\(^39,130\) In adult patients with ALL who only received intrathecal chemotherapy and intensive systemic chemotherapy for CNS prophylaxis, the overall CNS relapse rate was 2% to 6%.\(^8,10,46,164\) Therefore, with the incorporation of adequate systemic chemotherapy (e.g., high-dose methotrexate and cytarabine) and intrathecal chemotherapy regimens (e.g., methotrexate alone or with cytarabine and corticosteroid, which constitutes the triple intrathecal regimen), the use of upfront cranial irradiation can be avoided except in cases of overt CNS leukemia at presentation, and the use of irradiation can be reserved for salvage therapy settings. CNS prophylaxis is typically given throughout the course of ALL therapy starting from induction, to consolidation, to the maintenance phases of treatment.

**NCCN Recommendations for Evaluation and Treatment of Extramedullary Involvement**

Given the risks of neurologic adverse events associated with CNS-directed therapy, comprehensive neuropsychologic testing may be useful at baseline and during posttreatment follow-up. CNS involvement should be evaluated with lumbar puncture at the appropriate timing according to the specific treatment...
Response Assessment and Surveillance

Response Criteria

Response in Bone Marrow and Peripheral Blood: A CR requires the absence of circulating blasts and absence of extramedullary disease (i.e., no lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass, or CNS involvement). A bone marrow assessment should show trilineage hematopoiesis and fewer than 5% blasts. For a CR, absolute neutrophil counts (ANCs) should be greater than $1.0 \times 10^9/L$ and platelet counts should be greater than $100 \times 10^9/L$. In addition, no recurrence should be observed for at least 4 weeks. A patient is considered to have a CR if criteria for CR are met except for ANC less than $1.0 \times 10^9/L$ or platelets less than $100 \times 10^9/L$.

Refractory disease is defined as failure to achieve a CR at the end of induction therapy. Progressive disease is defined as an increase of at least 25% in the absolute number of circulating blasts (in peripheral blood) or bone marrow blasts, or the development of extramedullary disease. Relapsed disease is defined as the reappearance of blasts in the blood or bone marrow (> 5%) or in any extramedullary site after achievement of a CR.

Response in CNS Disease: Remission of CNS disease is defined as achievement of CNS-1 status (no lymphoblasts in CSF regardless of WBC count; CNS-2 is defined as WBC less than 5/mcL in CSF with presence of blasts; and CNS-3 is defined as WBC of 5/mcL or greater with presence of blasts. If the patient has leukemic cells in the peripheral blood and the lumbar puncture is traumatic (containing ≥ 5/mcL WBCs in CSF with blasts), then theSteinherz-Bleyer algorithm can be used to determine the CNS classification (if the WBC/RBC ratio in the CSF is at least 2-fold greater than the WBC/RBC ratio in the blood, then the classification would be CNS-3; if not, the classification would be CNS-2).

In general, patients with CNS involvement at diagnosis (i.e., CNS-3) should receive 18 Gy of cranial irradiation. In younger AYA patients with high-risk ALL [i.e., evidence of t(9;22) or BCR-ABL; t(4;11) or MLL-AF4] or T-cell ALL, use of prophylactic cranial irradiation may be an option. Notably, areas of the brain targeted by the radiation field in the management of patients with ALL are different from those targeted for brain metastases of solid tumors. In addition, patients with CNS leukemia at diagnosis should receive adequate systemic therapy, and intrathecal therapy containing methotrexate throughout the treatment course. Adequate systemic therapy should also be given in the management of patients with isolated CNS or testicular relapse.

A testicular examination should be performed for all male patients at diagnostic workup; testicular involvement is especially common among patients with T-cell ALL. Patients with clinical evidence of testicular disease at diagnosis that is not fully resolved by the end of induction therapy should be considered for radiation to the testes. Radiation therapy is typically performed concurrently with the first cycle of maintenance chemotherapy.
Acute Lymphoblastic Leukemia

Surveillance
After completion of the ALL treatment regimen (including maintenance therapy), the panel recommends surveillance at regular intervals to assess disease status. During the first year after completion of therapy, patients should undergo a complete physical examination and blood tests (CBC with differential) on a monthly basis. Liver function tests should be performed every 2 months until normal values are achieved. Assessment of bone marrow aspirate, CSF, and echocardiogram should be performed as clinically indicated; if a bone marrow aspirate is performed, comprehensive cytogenetics (including FISH), flow cytometry, and molecular tests should be considered. During the second year after completion of therapy, a physical examination (including a testicular examination for all male patients) and blood tests (CBC with differential) should be performed every 3 months. During the third year (and beyond) after completion of therapy, physical examination (including a testicular examination for all male patients) and blood tests (CBC with differential) can be performed every 6 months or as clinically indicated.

The COG has recently published guidelines on long-term survivorship issues for survivors of childhood cancers. These guidelines serve as a resource for clinicians and family members/caretakers, and have the goal of providing screening and management recommendations for late effects (e.g., those that may impact growth, cognitive function, emotional concerns, reproductive health, risks for secondary malignancies, and other important health issues) that may arise during the lifetime of an AYA cancer survivor as a result of the therapeutic agents used during the course of antitumor treatment.

Role of MRD Evaluation
MRD in ALL refers to the presence of leukemic cells below the threshold of detection using conventional morphologic methods. Patients who experienced a CR according to morphologic assessment alone can potentially harbor a large number of leukemic cells in the bone marrow: up to $10^{10}$ malignant cells. The most frequently used methods for MRD assessment include multicolor flow cytometry to detect abnormal immunophenotypes and PCR assays to detect clonal rearrangements in immunoglobulin heavy chain genes and/or T-cell receptor genes. Current flow cytometry or PCR methods can detect leukemic cells at a sensitivity threshold of less than $1 \times 10^{-4}$ ($<0.01\%$) bone marrow mononuclear cells. The concordance rate for detecting MRD between these methods is high. In a study that analyzed MRD using both flow cytometry and PCR in 1375 samples from 227 patients with ALL, the concordance rate for MRD assessment (based on a detection threshold of $<1 \times 10^{-4}$ for both methods) was 97%. However, high-sensitivity PCR assays require the identification of patient-specific markers that involve direct sequencing, and may therefore be labor- and resource-intensive for routine application in the clinical practice setting. Numerous studies in both childhood and adult ALL have shown the prognostic importance of postinduction (and/or postconsolidation) MRD measurements in predicting the likelihood of disease relapse.

MRD Assessment in Childhood ALL
Among children with ALL who achieve a CR according to morphologic evaluation after induction therapy, approximately 25% to 50% may still have detectable MRD based on sensitive assays (in which the threshold of MRD negativity is $<1 \times 10^{-4}$ bone marrow mononuclear cells). An early study in children with ALL ($N = 178$) showed that patients with detectable MRD after initial induction therapy (42% of patients) had significantly shorter time to relapse than patients with MRD-negative status ($P < .001$), which was defined based on a sensitivity level of less than $1.5 \times 10^{-4}$ according to PCR methods. Patients with MRD after induction also had a 10-fold increase in risk of death compared with those without detectable MRD. Moreover, the level of detectable MRD was found to be correlated with relapse; patients with MRD of $1 \times 10^{-2}$ or greater had a 16-fold higher risk of relapse compared with those who had MRD levels of less than $1 \times 10^{-3}$. In another study in children with ALL ($N = 158$), patients with detectable MRD (measured through flow cytometry with sensitivity level $<1 \times 10^{-4}$) at the end of induction therapy had a significantly higher 3-year cumulative incidence of relapse than those who were MRD negative (33% vs. 7.5%; $P < .001$). Subsequent studies have confirmed these findings. In
a study of patients (N = 165) with MRD assessment (measured through flow cytometry with sensitivity level < 1 × 10^−4) after induction therapy, the 5-year relapse rate was significantly higher among patients with MRD versus those without detectable disease (43% vs. 10%; P < .001).\textsuperscript{169} In addition, the persistence of MRD during the course of therapy was associated with risks of relapse in this study; the cumulative rate of relapse was significantly higher among patients with MRD persisting through week 14 of continued treatment compared with patients who became MRD-negative by this point (68% vs. 7%; P = .035).\textsuperscript{170} MRD evaluation was shown to be a significant independent predictor of outcomes in this study.

MRD assessments at an earlier time point in the course of treatment (e.g., during induction therapy) was also shown to be highly predictive of outcomes in children with ALL. In one study, nearly 50% of patients had MRD clearance (in which MRD negativity was defined as < 1 × 10^−4 through flow cytometry) by day 19 of induction therapy (about 2–3 weeks from initiation of induction); the 5-year cumulative incidence of relapse was shown to be significantly higher among patients with MRD at day 19 of treatment than those without detectable MRD (33% vs. 6%; P < .001).\textsuperscript{169} More recently, the prognostic significance of MRD detection at lower levels (sensitivity threshold, ≤ 1 × 10^−5, or ≤ 0.001%, according to PCR) was evaluated in children with B-cell lineage ALL treated with contemporary regimens.\textsuperscript{173} At the end of induction therapy, 58% of patients had undetectable disease on PCR. Among the remaining patients with detectable MRD, 17% had MRD of 0.01% or greater, 14% had less than 0.01% (but ≥ 0.001%), and 11% had less than 0.001%. The 5-year cumulative incidence of relapse was significantly higher among patients with MRD of 0.01% or greater versus those with less than 0.01% or undetectable disease (23% vs. 6%; P < .001).\textsuperscript{173} Furthermore, the 5-year cumulative incidence of relapse was significantly higher among the subgroup of patients with MRD less than 0.01% (but ≥ 0.001%) compared with those with MRD less than 0.001% or undetectable disease (13% vs. 5%; P < .05). MRD status at the end of induction therapy was strongly correlated with MRD levels (measured on flow cytometry with sensitivity level < 0.01%) at day 19 during induction; all patients who had MRD of 0.01% or greater at the end of induction had MRD of 0.01% or greater at day 19 based on flow cytometry. Although this study showed a higher risk of relapse among the patients with MRD below the generally accepted threshold level (< 0.01% but ≥ 0.001%) compared with those with very low MRD (< 0.001%) or no detectable disease, whether this lower threshold should be used to risk stratify patients or guide decisions surrounding treatment intensification is currently unknown.\textsuperscript{173}

In one of the largest collaborative studies conducted in Europe (the AIEOP-BFM ALL 2000 study), children with Ph-negative B-cell lineage ALL (N = 3184 evaluable) were risk stratified according to MRD status (measured on PCR with sensitivity level ≤ 0.01%) at 2 time points, days 33 and 78, which were then used to guide postinduction treatment.\textsuperscript{174} Patients were considered standard risk if MRD negativity (≤ 0.01%) was achieved at both days 33 and 78, intermediate risk if MRD was greater than 0.01% (but < 0.1%) on either day 33 or 78 (the other time point being MRD-negative) or on both days 33 and 78, and high risk if MRD was 0.1% or greater on day 78. Nearly all patients with favorable cytogenetic/molecular markers such as the TEL-AML1 subtype or hyperdiploidy were either standard risk or intermediate risk based on MRD evaluation.\textsuperscript{174} The 5-year EFS rate was 92% for patients categorized as standard-risk (n = 1348), 78% for intermediate-risk (n = 1647), and 50% for high-risk patients (n = 189; P < .001); the 5-year OS rates were 98%, 93%, and 60%, respectively. MRD-based risk stratification was able to significantly differentiate risks for relapse (between standard- and intermediate-risk subgroups) even among patient populations with TEL-AML1 or hyperdiploidy. Importantly, MRD remained a significant and powerful independent prognostic factor for relapse in the overall population in this large-scale study.\textsuperscript{174}

Several studies have suggested that an early assessment of MRD during induction treatment (e.g., day 15 from initiation of treatment) may be highly predictive of subsequent relapse in children with ALL.\textsuperscript{175,176} This raises the possibility of identifying high-risk patients who may potentially benefit from earlier intensification or tailoring of treatment regimens, or for potentially allowing less-intensive treatments to be administered in patients at low risk for relapse based on early MRD measurements. Large trials are warranted to address these possibilities, al-
though serial MRD measurements very likely may still be needed to monitor leukemic cell kinetics during the long course of treatment in ALL.

Approximately 20% of children treated with intensive therapies for ALL will ultimately experience disease relapse.\textsuperscript{177} MRD assessment may also play a prognostic role in the management of patients in the relapsed setting.\textsuperscript{178,179} In patients (N = 35) who experienced a second remission (morphologic CR) after reinduction treatment, MRD (measured on flow cytometry with sensitivity level < 0.01%) after reinduction (day 36) was significantly associated with risks for relapse; the 2-year cumulative incidence of relapse was 70% among patients with MRD of 0.01% or greater, versus 28% among those with MRD less than 0.01% (P = .008).\textsuperscript{179} In addition, among the subgroup of patients who experienced first relapse after cessation of treatment, the 2-year cumulative incidence of second relapse was 49% among those with MRD of 0.01% or greater, versus 0% for those with MRD less than 0.01% (P = .014). Both the presence of MRD at day 36 of reinduction therapy and first relapse occurring during therapy were significant independent predictors of second relapse based on multivariate analysis.\textsuperscript{178} In another study, MRD (measured on PCR with sensitivity level < 0.01%) was evaluated in high-risk children with ALL (N = 60) who experienced first relapse within 30 months from the time of diagnosis.\textsuperscript{179} Categories based on MRD evaluation after the first chemotherapy cycle (3–5 weeks after initiation of reinduction treatment) included MRD negativity (undetectable MRD), MRD positive but unquantifiable (levels < 0.01%), and MRD of 0.01% or greater. The 3-year EFS rate based on these MRD categories was 73%, 45%, and 19%, respectively (P < .05).\textsuperscript{179} Thus, MRD assessment can identify patients with a high probability of second relapse, which may offer an opportunity for risk-adapted second-line treatment strategies in these patients.

**MRD Assessment in Adult ALL**

Studies in adults with ALL have also shown the strong correlation between MRD and risks for relapse, and the prognostic significance of MRD measurements during and after initial induction therapy.\textsuperscript{166,180–183} In an analysis of postinduction MRD (measured on flow cytometry with sensitivity level < 0.05%) in adult patients with ALL (N = 87), median relapse-free survival was significantly longer among patients with MRD less than 0.05% at day 35 compared with those with MRD of 0.05% or greater (42 vs. 16 months; P = .001).\textsuperscript{183} A similar pattern emerged when only the subgroup of patients with morphologic CR at day 35 was included in the MRD evaluation. Additionally, although patient numbers were limited, 90% of patients with MRD less than 0.03% at an earlier time point (at day 14, during induction therapy) remained relapse-free at 5 years.\textsuperscript{183} MRD after induction therapy was also found to be significantly predictive of relapse in a subgroup analysis from the MRC UKALL/ECOG study. In patients with Ph-negative B-cell lineage ALL (N = 161) whose data were analyzed for MRD evaluation (measured on PCR with sensitivity level < 0.01%), the 5-year relapse-free survival rate was significantly higher in patients with MRD negativity versus those with MRD of 0.01% or greater (71% vs. 15%; P = .0002).\textsuperscript{182} Postinduction MRD has been shown to serve as a significant independent predictor of relapse even among adult patients considered to be at standard risk based on traditional prognostic factors. In a study of adult patients with Ph-negative ALL (N = 116 evaluable), MRD status after induction therapy (measured on flow cytometry with sensitivity level < 0.1%) was significantly predictive of relapse regardless of whether the patient was considered at standard risk or high risk at initial evaluation.\textsuperscript{181} Among the patients who were initially classified as having standard risk, those with MRD of less than 0.1% after induction had significantly lower risk of relapse at 3 years compared with patients with higher levels of MRD (9% vs. 71%; P = .001). Interestingly, this study also showed that MRD measured during the postconsolidation time point was not significantly predictive of outcomes.\textsuperscript{181}

In a study by the German Multicenter ALL (GMALL) Study Group, patients with standard-risk disease (N = 148 evaluable) were monitored for MRD (measured on PCR with sensitivity level < 0.01%) at various time points during the first year of treatment (GMALL 06/99 study).\textsuperscript{182} Only patients with ALL who met all of the following criteria for standard risk were enrolled in this study: absence of t(4;11) MLL translocation or t(9;22) BCR-ABL translocation; WBC count less than 30 × 10^9/L for B-cell lineage ALL or less than 100 × 10^9/L for T-cell lineage ALL; age 15 to 65 years; and achievement of morphologic CR after phase I of induction treatment. At the end of initial induction therapy (at day 24), patients with MRD of 0.01% or greater had a 2.4-fold higher risk
(95% CI, 1.3–4.2) of relapse than those with MRD of less than 0.01%. Moreover, this study identified distinct risk groups according to MRD status at various time points. Patients categorized as low risk (10% of study patients) had MRD of less than 0.01% at both days 11 and 24 (during and after initial induction), and had 3-year DFS and OS rates of 100% (for both end points). Patients in the high-risk group (23%) had MRD of 0.01% or greater persisting through week 16, and had a 3-year DFS and OS rates of only 6% and 45%, respectively. All other patients (67%) were categorized as having intermediate risk, and had 3-year DFS and OS rates of 53% and 70%, respectively. Importantly, a multivariate Cox regression analysis that included gender, age, WBC count, B- or T-cell lineage, and MRD in the model showed that MRD was the only independently significant predictor of outcomes in this patient population. Thus, MRD evaluation postinduction may provide further risk stratification information among patients who are otherwise considered standard risk according to traditional evaluation of prognostic factors.

MRD assessment after consolidation therapy has also been shown to have prognostic significance, offering the possibility to adjust postconsolidation treatment approaches. In a recent study that evaluated MRD (measured by PCR with sensitivity level < 0.01% after consolidation therapy (weeks 16–22 from initiation of induction) in adult patients with ALL (N = 142), patients with MRD of less than 0.01% (n = 58) were primarily allotted to receive maintenance chemotherapy for 2 years, whereas those with MRD of 0.01% or greater (n = 54) were eligible to undergo allogeneic HSCT after high-dose therapy. The 5-year DFS rate was significantly higher among patients with MRD negativity versus those with MRD of 0.01% or greater (72% vs. 14%; P = .001); similarly, the 5-year OS rate was significantly higher for patients with MRD-negative status postconsolidation (75% vs. 33%; P = .001). In a follow-up study of the GMALL 06/99 study mentioned earlier, patients with standard-risk ALL (as defined by Brugemann et al.) who experienced MRD negativity (< 0.01% leukemic cells on PCR) during the first year of treatment underwent sequential MRD monitoring during maintenance therapy and follow-up. Among the patients included in this analysis (N = 105), 28 (27%) became MRD-positive after the first year of therapy; MRD was detected before hematologic relapse in 17 of these patients. The median relapse-free survival was 18 months (calculated from the end of initial treatment) among the subgroup that became MRD-positive, whereas the median has not yet been reached among patients who remained MRD-negative. The median time from MRD positivity (at any level, including nonquantifiable cases) to clinical relapse was 9.5 months; the median time from quantitative MRD detection to clinical relapse was even shorter, at 4 months. This study showed that detection of postconsolidation MRD was highly predictive of subsequent hematologic relapse and introduced the concept of molecular relapse in ALL. However, the potential advantage of intensifying or modifying treatment regimens (e.g., incorporation of allogeneic HSCT) based on identification of a molecular relapse remains to be investigated.

Studies in children and adult patients with ALL suggest that differences may exist in the kinetics of leukemic cell eradication between these patient populations. Among children treated on contemporary regimens, 60% to 75% experienced clearance of MRD (on sensitive flow cytometry or PCR assays) at the end of induction therapy (typically corresponding to 5–6 weeks after initiation of induction). In one study, nearly 50% of children had MRD clearance (< 0.01% on flow cytometry) at day 19 of induction therapy. Adult patients seem to have a slower rate of leukemic cell clearance compared with children, with 30% to 50% of adult patients having MRD negativity after initial induction. Approximately 50% of patients remained MRD-positive at 2 months after initiation of induction, with further reductions in proportion of MRD-positive patients occurring beyond 3 to 5 months. These differences in the kinetics of leukemic cell reduction in the bone marrow may, at least partly, be attributed to differences in therapeutic regimens, variations in the distribution of immunophenotypic or cytogenetic/molecular features, and other host factors.

NCCN Recommendations for MRD Assessment Collectively, the studies discussed earlier show the high prognostic value of MRD in assessing risks for relapse in patients with ALL, and the potential role of MRD monitoring in identifying subgroups of patients who may benefit from further intensified therapies or alternative treatment strategies. As previously discussed, current flow cytometry or PCR methods can detect leukemic cells at a sensitivity threshold of fewer than $1 \times 10^{-4}$ (< 0.01%) bone marrow mono-
nuclear cells (MNCs).\textsuperscript{187,188} The concordance rate for detecting MRD between these methods is high. However, high-sensitivity PCR assays (for analysis of immunoglobulin or T-cell receptor gene rearrangements) require the identification of patient-specific markers that involve direct sequencing, and may therefore be labor- and resource-intensive for routine application in the clinical practice setting. Recommendations on the minimal technical requirements for MRD assessment (both for PCR and flow cytometry methods) and definitions for response based on MRD results (e.g., MRD negativity, nonquantifiable MRD positivity, quantifiable MRD positivity) were published recently as a result of a consensus meeting held by ALL study groups across Europe.\textsuperscript{187} The recommendations were made in an effort to standardize MRD measurements and reporting of MRD data within the context of clinical trials. The panel strongly recommends that MRD assessments be performed at specialized treatment centers with access to reference laboratories that have expertise in MRD assays.

The timing of MRD assessment varies depending on the ALL treatment protocol being used, and may occur during or after completion of initial induction therapy. If MRD is being evaluated, the initial measurement should be performed on completion of induction therapy; additional time points for MRD evaluation may be useful depending on the specific treatment protocol or regimen used. For MRD evaluation on multicolor flow cytometry, sampling of bone marrow MNCs is preferred over peripheral blood samples. At least $1 \times 10^6$ MNCs are required for analysis (~ 2 mL of bone marrow or 5–10 mL of peripheral blood provides sufficient number of cells for multiple analysis).\textsuperscript{187,188} For MRD evaluation with real-time quantitative PCR (RQ-PCR), sampling of bone marrow MNC is preferred. At least $1 \times 10^7$ MNCs are required for initial marker characterization and generation of individual dilution series; $1 \times 10^6$ MNCs are sufficient for follow-up analysis.\textsuperscript{187} The minimal limit of assay sensitivity (to declare MRD negativity) should be less than $1 \times 10^{-4}$ (< 0.01%).

Supportive Care for Patients With ALL

Given the highly complex and intensive treatment protocols used in the management of ALL, supportive care issues are important considerations to ensure that patients derive the most benefit from ALL therapy. Although differences may exist between institutional standards and practices, supportive care measures for patients with ALL generally include the use of antiemetics for prevention of nausea and vomiting, blood product transfusions or cytokine support for severe cytopenias, nutritional support for prevention of weight loss, gastroenterology support, pain management, prevention and management of infectious complications, and prophylaxis for TLS. In addition, both short- and long-term consequences of potential toxicities associated with specific agents used in ALL regimens should be considered, such as with steroids (e.g., risks for hyperglycemia or peptic ulcerations in the acute setting; risks for osteonecrosis or avascular necrosis with long-term use) and asparaginase (e.g., risks for hypersensitivity reactions, hyperglycemia, coagulopathy, hepatotoxicity, and/or pancreatitis). Supportive care measures should be tailored to meet the individual needs of each patient based on factors such as age, performance status, extent of cytopenias before and during therapy, risks for infectious complications, disease status, and the specific agents used in the ALL treatment regimen (see page 868).

NCCN Recommendations for Supportive Care

Most chemotherapy regimens used in ALL contain agents that are at least moderately emetogenic, which may necessitate antiemetic support before initiating emetogenic chemotherapy. Antiemesis prophylaxis may include the use of agents such as serotonin receptor antagonists, corticosteroids, and/or neurokinin-1–receptor antagonists. Recommendations for antiemetic support for patients receiving chemotherapy are available in the NCCN Guidelines for Antiemesis (to view the most recent version of these guidelines, visit NCCN.org). For patients with ALL, the routine use of corticosteroids as part of antiemetic therapy should be avoided given that steroids constitute a major component of ALL regimens. For patients experiencing greater than 10% weight loss, enteral or parenteral nutritional support should be considered. Regimens to maintain bowel movement and prevent the occurrence of constipation may need to be considered for some patients. Daily doses of docusate sodium may be useful, and laxatives should be administered promptly when symptoms arise.
Acute Lymphoblastic Leukemia

For patients requiring transfusion support for severe or prolonged cytopenias, only irradiated blood products should be used. Growth factor support (granulocyte colony-stimulating factor; filgrastim 5 mcg/kg/d subcutaneously) is recommended during blocks of myelosuppressive therapy or as directed by the treatment protocol being followed for individual patients.

Patients with ALL undergoing intensive chemotherapy or allogeneic HSCT are highly susceptible to infections. Immunosuppression caused by the underlying disease and therapeutic regimens can predispose patients to common bacterial and viral infections, and to various opportunistic infections (e.g., candidiasis, invasive mold infections, Pneumocystis jirovecii, cytomegalovirus reactivation, and infection), particularly during periods of prolonged neutropenia. Patients with ALL should be closely monitored for any signs or symptoms of infections. Cases of febrile neutropenia should be managed promptly with empiric anti-infectives and inpatient admission. Recommendations for the prevention and management of infections in patients with cancer are available via the NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections (to view the most recent version of these guidelines, visit NCCN.org).

For patients with ALL, antibacterial prophylaxis with a fluoroquinolone (levofloxacin is preferred) should be considered in those with expected duration of neutropenia (ANC < 1000/mcL) of more than 7 days. Antiviral prophylaxis (acyclovir, valacyclovir, or famciclovir) is recommended in herpes simplex virus (HSV)–seropositive patients receiving induction/consolidation chemotherapy, and during neutropenia, and at least 30 days after allogeneic HSCT. A longer period of prophylaxis may need to be considered in allogeneic HSCT recipients with graft-versus-host disease (GVHD) or with frequent HSV reactivations before transplantation. In addition, varicella zoster virus (VZV) prophylaxis with acyclovir during the 12-month period after allogeneic HSCT may be considered in patients who are VZV-seropositive pretransplant; agents used for HSV prophylaxis are generally also active against VZV.

Antifungal prophylaxis with fluconazole (category 2A) or amphotericin B agents (category 2B) should be considered for all patients with ALL treated with chemotherapy (see the NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections; available at NCCN.org). If an amphotericin B product is used for antifungal prophylaxis, a lipid formulation is generally preferred because of less infusional and renal toxicity compared with conventional amphotericin B. Antifungal prophylaxis with posaconazole,itraconazole, and voriconazole should be avoided in patients receiving vinca alkaloids (e.g., vincristine, which is included as a component of nearly all treatment regimens for ALL) because of the potential of these azoles to inhibit the cytochrome P450 3A4 isoenzyme, potentially reducing clearance of vinca alkaloids. Fluconazole prophylaxis has been shown to be effective in controlling yeast colonization and decreasing the rate of mucosal candidiasis and invasive Candida infections in patients receiving allogeneic HSCT.189–191 For patients undergoing allogeneic HSCT, antifungal prophylaxis with fluconazole or micafungin (both category 1) should be considered until at least day 75 after HSCT; other azoles or amphotericin B agents in this setting are considered category 2B recommendations (see the NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections; available at NCCN.org). Trimethoprim/sulfamethoxazole (TMP-SMX) for P. jirovecii prophylaxis is effective in preventing Pneumocystis pneumonia in patients with acute leukemias,192,193 and should be considered for all patients receiving chemotherapy for ALL.

Cytomegalovirus surveillance should be strongly considered during chronic GVHD requiring immunosuppressive therapy and until the CD4-positive count is 100/mcL or greater (see the NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections; available at NCCN.org). It is important to note that the local susceptibility and resistance patterns of pathogens must be considered in the choice of anti-infective agents used for the prevention or treatment of infections.

Patients with ALL may be at high risk for developing acute TLS, particularly those with highly elevated WBC counts before induction chemotherapy. TLS is characterized by metabolic abnormalities stemming from the sudden release of intracel-
lular contents into the peripheral blood because of cellular disintegration induced by chemotherapy. If left untreated, TLS can result in profound metabolic changes leading to cardiac arrhythmias, seizures, loss of muscle control, acute renal failure, and even death. Recommendations for the management of TLS are available in the “Tumor Lysis Syndrome” section of the NCCN Guidelines for NHL (available at NCCN.org [NHODG-B]). Standard prophylaxis for TLS includes hydration with diuresis, alkalinization of the urine, and treatment with allopurinol or rasburicase. Rasburicase should be considered as initial treatment in patients with rapidly increasing blast counts, high uric acid, or evidence of impaired renal function. Although relatively uncommon in patients with ALL, symptomatic hyperleukocytosis (leukostasis) constitutes a medical emergency and requires immediate treatment, as recommended in the NCCN Guidelines for Acute Myeloid Leukemia (available at NCCN.org). Leukostasis is characterized by highly elevated WBC count (usually > 100 × 10⁹/L) and symptoms of decreased tissue perfusion that often affects respiratory and CNS function. Although leukapheresis is not typically recommended in the routine management of patients with high WBC counts, it can be considered with caution in cases of leukostasis unresponsive to other interventions.

Key components of the ALL treatment regimen, such as corticosteroids and asparaginase, are associated with unique toxicities that require close monitoring and management. Corticosteroids, such as prednisone and dexamethasone, constitute a core component of nearly all ALL induction regimens, and are also frequently incorporated into consolidation and/or maintenance regimens. Acute side effects of steroids may include hyperglycemia and steroid-induced diabetes mellitus. Patients should be monitored for glucose control using the Insulin Sliding Scale (ISS) to minimize the risks for developing infectious complications. Another acute side effect of steroid therapy includes peptic ulceration and dyspeptic symptoms; the use of histamine-2 receptor antagonists or proton pump inhibitors is recommended during steroid therapy to reduce these risks. A potential long-term side effect associated with steroid therapy includes osteonecrosis/avascular necrosis. Osteonecrosis most often affects weight-bearing joints, such as the hip and/or knee, and seems to have a higher incidence among adolescents (presumably because of the period of skeletal growth) than younger children or adults. Routine measurements for vitamin D and calcium levels should be obtained, and periodic radiographic evaluation (using plain films or MRI) should be considered to monitor the risks for osteonecrosis.

Asparaginase is also a core component of ALL regimens, most often given during induction and consolidation for Ph-negative disease. Several different formulations of the enzyme are available, including the native asparaginase derived from *Escherichia coli*, a pegylated form of the *E. coli*–derived asparaginase, PEG-asparaginase, and *Erwinia* asparaginase derived from a different Gram-negative bacteria *Erwinia chrysanthemi*. These formulations differ in their pharmacologic properties, and may also differ in terms of immunogenicity. Regardless of the formulation, asparaginase can be associated with potentially severe hypersensitivity reactions (including anaphylaxis) arising from the production of anti-asparaginase antibodies. PEG-asparaginase seems to be associated with a lower incidence of neutralizing antibodies compared with native asparaginase. However, cross-reactivity between neutralizing antibodies against native *E. coli* asparaginase and PEG-asparaginase have been reported. Moreover, a recent study showed that high anti-asparaginase antibody level after initial therapy with native *E. coli* asparaginase was associated with decreased asparaginase activity during subsequent therapy with PEG-asparaginase. In contrast, no cross-reactivity between antibodies against native *E. coli* asparaginase and *Erwinia* asparaginase was reported, and enzyme activity of *Erwinia* asparaginase was not affected by the presence of anti-*E. coli* asparaginase antibodies. A study from the DFCI ALL Consortium showed the feasibility and activity of using *Erwinia* asparaginase in pediatric and adolescent patients who developed hypersensitivity reactions to *E. coli* asparaginase during frontline therapy; importantly, treatment with *Erwinia* asparaginase did not negatively impact EFS outcomes in these patients. Thus, for patients who develop severe hypersensitivity reactions during treatment with *E. coli* asparaginase (either to the native or pegylated formulation), the use of *E. coli*–derived formulations should be stopped and *Erwinia* asparaginase should be substituted (see “Sup-
Supportive Care: Asparaginase Toxicity Management” on page 868). *Erwinia* asparaginase is currently approved by the FDA for patients with ALL who have developed hypersensitivity to *E. coli*–derived asparaginase.\(^\text{205}\) Asparaginase can also be associated with various toxicities, including pancreatitis (e.g., ranging from asymptomatic cases with amylase or lipase elevation, to symptomatic cases with vomiting or severe abdominal pain), hepatotoxicity (e.g., increase in alanine or glutamine aminotransferase), and coagulopathy (e.g., thrombosis, hemorrhage). Detailed recommendations for the management of asparaginase toxicity in AYA and adult patients were published recently,\(^\text{199}\) and have been incorporated into these guidelines (see “Supportive Care: Asparaginase Toxicity Management” on page 868).

### References

Acute Lymphoblastic Leukemia


Acute Lymphoblastic Leukemia


86. Takayama N, Sato N, O'Brien SG, et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic


Acute Lymphoblastic Leukemia


Acute Lymphoblastic Leukemia


174. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and...


### Individual Disclosures for the NCCN Guidelines Acute Lymphoblastic Leukemia Panel Members

<table>
<thead>
<tr>
<th>Panel Member</th>
<th>Clinical Research Support</th>
<th>Advisory Boards, Speakers Bureau, Expert Witness, or Consultant</th>
<th>Patent, Equity, or Royalty</th>
<th>Other</th>
<th>Date Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph C. Alvarnas, MD</td>
<td>Clinical Trials Network</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>None</td>
<td>None</td>
<td>5/11/11</td>
</tr>
<tr>
<td>Patricia Aoun, MD, MPH</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>3/15/12</td>
</tr>
<tr>
<td>Karen Kuhn Ballen, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>3/7/12</td>
</tr>
<tr>
<td>Naresh Bellam, MD, MPH</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2/9/12</td>
</tr>
<tr>
<td>William Blum, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5/11/11</td>
</tr>
<tr>
<td>Michael W. Boyer, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5/11/11</td>
</tr>
<tr>
<td>Patrick A. Brown, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>1/3/12</td>
</tr>
<tr>
<td>Hetty E. Carraway, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>3/13/12</td>
</tr>
<tr>
<td>Peter F. Coccia, MD</td>
<td>None</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>None</td>
<td>None</td>
<td>9/27/11</td>
</tr>
<tr>
<td>Steven E. Coutre, MD</td>
<td>None</td>
<td>Celgene Corporation; and Novartis Pharmaceuticals Corporation</td>
<td>None</td>
<td>None</td>
<td>3/8/12</td>
</tr>
<tr>
<td>Jennifer Cultrerera, MD</td>
<td>Southwest Oncology Group</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>4/30/12</td>
</tr>
<tr>
<td>Lloyd E. Damon, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>10/13/11</td>
</tr>
<tr>
<td>Daniel J. DeAngelo, MD, PhD</td>
<td>None</td>
<td>Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; and Sigma-Tau Pharmaceuticals, Inc.</td>
<td>None</td>
<td>None</td>
<td>3/16/12</td>
</tr>
<tr>
<td>Dan Douer, MD</td>
<td>Enzon Pharmaceuticals</td>
<td>Enzon Pharmaceuticals</td>
<td>None</td>
<td>None</td>
<td>4/8/11</td>
</tr>
<tr>
<td>Haydar Frangoul, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5/1/11</td>
</tr>
<tr>
<td>Olga Frankurt, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>1/25/12</td>
</tr>
<tr>
<td>Salil Goorha, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>3/7/12</td>
</tr>
<tr>
<td>Michael M. Millenson, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>4/6/11</td>
</tr>
<tr>
<td>Susan O’Brien, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>7/27/11</td>
</tr>
<tr>
<td>Stephen H. Petersdorf, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>3/27/12</td>
</tr>
<tr>
<td>Arati V. Rao, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>3/9/12</td>
</tr>
<tr>
<td>Stephanie Terezakis, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5/12/11</td>
</tr>
<tr>
<td>Geoffrey Uy, MD</td>
<td>Genzyme Corporation; and Novartis Pharmaceuticals Corporation</td>
<td>Genzyme Corporation</td>
<td>None</td>
<td>None</td>
<td>3/7/12</td>
</tr>
<tr>
<td>Meir Wetzler, MD</td>
<td>Bristol-Myers Squibb Company; and ChemGenex Pharmaceuticals Ltd</td>
<td>Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; and ChemGenex Pharmaceuticals Ltd</td>
<td>None</td>
<td>None</td>
<td>6/2/11</td>
</tr>
<tr>
<td>Andrew D. Zelenetz, MD, PhD</td>
<td>Abbott Laboratories; Celgene Corporation; Cephalon, Inc.; Genentech, Inc.; GlaxoSmithKline; Millennium Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.; Allos Therapeutics, Inc.; Calistoga Pharmaceuticals; Pharmacyclics, Inc.; Flexelox Inc; Roche; and Seattle Genetics</td>
<td>Abbott Laboratories; Celgene Corporation; Cell Therapeutics, Inc.; Cephalon, Inc.; Genentech, Inc.; GlaxoSmithKline; Allos Therapeutics, Inc.; Cancer Genetics; Gilead Sciences, Inc.; Seattle Genetics; Roche Laboratories, Inc.; and sanofi-aventis U.S.</td>
<td>None</td>
<td>None</td>
<td>2/15/12</td>
</tr>
</tbody>
</table>

The NCCN guidelines staff have no conflicts to disclose.